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Abstract
The manipulation of large (>10 kb) plasmid systems amplifies problems common to
traditional cloning strategies. Unique or rare restriction enzyme recognition sequences are
uncommon and very rarely located in opportunistic locations. Making site-specific deletions and
insertions in larger plasmids consequently leads to multiple step cloning strategies that are often
limited by time-consuming, low efficiency linker insertions or blunt-end cloning strategies.
Manipulation of the adenovirus genome and the genomes ofother viruses as bacterial plasmids are
systems that typify such situations.
Recombinational cloning techniques based on homologous recombination in
Saccharomyces cerevisiae that circumvent many ofthese common problems have been
developed. However, these techniques are rarely realistic options for such large plasmid systems
due to the above mentioned difficulties associated with the addition of required yeast DNA
replication, partitioning and selectable marker sequences.
To determine ifrecombinational cloning techniques could be modified to simplify the
manipulation of such a large plasmid system, a recombinational cloning system for the creation of
human adenovirus E I-deletion rescue plasmids was developed.
Here we report for the first time that the 1,456 bp TRP1/ARS fragment of YRp7 is alone
sufficient to foster successful recombinational cloning without additional partitioning sequences,
using only slight modifications of existing protocols. In addition, we describe conditions for
efficient recombinational cloning involving simultaneous deletion of large segments ofDNA (>4.2
kb) and insertion of donor fragment DNA using only a single non-unique restriction site.
The discovery that recombinational cloning can foster large deletions has been used to
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develop a novel recombiliational cloillng technique, selectable inarker 'kilockouf" recombinational
cloning, that uses deletion of a yeast selectable marker coupled with simultaneous negative and
positive selection to reduce background transformants to undetectable levels.
The modification of existing protocols as described in this report facilitates the use of
recombinational cloning strategies that are otherwise difficult or impractical for use with large
plasmid systems. Improvement of general recombinational cloning strategies and strategies
specific to the manipulation of the adenovirus genome are considered in light of data presented
herein.
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1. IntroductIon and Literature Review
I.A.I History and Classification of the Family Adenoviridae
Adenoviruses are non-enveloped~ linear double-stranded DNA viruses encapsidated in an
icosahedron protein shell measuring from 70 to 100 nm in diameter. These viruses cause mild
self-limiting infections of the upper respiratory tract, epidemic conjunctivitis~ and have been
associated with a variety of additional clinical conditions- perhaps most notably~ infantile
gastroenteritis. The discovery of the adenoviruses dates back to 1953~ when Rowe and
colleagues observed spontaneous degeneration ofprimary human adenoid cell cultures while
examining the causative agents of acute respiratory illness. Similarly, in 1954 Hilleman and
Werner isolated agents responsible for cytopathic changes in human cell culture while examining
an epidemic of respiratory ailments in military recruits. These agents of respiratory disease were
subsequently shown to be viral in origin and were named adenoviruses after the original tissue
source from which they were isolated (reviewed in Shenk, 1996).
Since the discovery of the first adenovirus, other viruses sharing similar properties have
been grouped together in the family Adenoviridae. The genera in this family have been
categorized based on infectivity in birds (Aviadenovirus genus)~ and a number ofdifferent animal
species including human~ simian~ bovine, equine, porcine, ovine, canine, and opossum
(Mas/adenovirus genus). Antigenic similarities do exist between genera~ however there is no
known antigen common among all adenoviruses. The various human serotypes (to date, 49
human serotypes) have been distinguished on the basis ofantibody cross-reactivity,
hemagglutination, oncogenicity, viral protein electrophoretic mobility, and/or genomic
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composition (GC c6~ntel1t, cross-hybridization., restriction endonuclease digestion patterns). Table
1.1 summarizes one such classification scheme for the human adenoviruses.
Table 1.1: Classification schemes for human adenoviruses (reproduced from Shenk., 1996).
Subgenus Serotype G+C. Hemagglutinatiof.l Lengt~. qncoge~icity .' _~ '. Tropism
'. ::(%) •.~.. _. :c~a~e~n •. ":' .. Fi~~~s' :i~~~:~~~n:··>~:.sYmPtoms :,y.
- _ ". nm ' ..,'
A 12,18,31 48 IV 28-31 High Cryptic enteric
infection
B 3,7,11,14, 51 9-11 Weak Respiratory
16,21,34, Disease, Persistent
35 infections of the
kidneys
C 1,2,5,6 58 III 23-31 Nil Respiratory
disease persists in
lymphoid tissues
o 8,9,10,13, 58 II 12-13 Nil Keratoconjunctivitis
15,17,19,
20,22 to
30,32,33,
36,37,38,
39,42 to
47
E 4 58 III 17 Nil Conjunctivitis,
Respiratory
disease
F 40.41 52 IV 28-33 Nil Infantile diarrhea
In 1962 human adenovirus research attained new levels of attention as Trentin and his
colleagues demonstrated that human adenovirus type 12 was capable of inducing malignant
tumours in newborn hamsters. This was the first reported instance in which a human virus was
capable ofbeing oncogenic. And though the extensive searches for adenovirus DNA in human
tumours have virtually all failed to link the virus to malignant disease in humans, the use ofhuman
adenoviruses as a model system to probe the genetic regulation of oncogenesis in animal and
culture sys~ems has added substantially to our understanding of gene expression (both viral and
cellular), DNA replication, cell cycle control, and cell growth regulation (reviewed in Shenk,
1996).
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Undoubt~diy~-the- single largest contribution made to· m6de-rn -biologyoy the adenovirus
system was the discovery ofmRNA splicing. The ability of the viral genome to give rise to a
multitude of viral mRNAs generated from one larger nuclear transcript revealed the existence of
introns and exons, and fostered a new appreciation of the intricacies of eukaryotic gene
expressIon.
From its original discovery as a human pathogen, the adenoviruses may yet yield one of
humankind's greatest medical achievements. The use of modified adenovirus vectors as tools for
the delivery of therapeutic genes is currently under intensive exploration.
The following sections will briefly outline the virus particle and genomic organization,
infectious cycle, and the other aspects ofadenovirus biology relevant to the use ofthe human
adenovirus -as a gene therapy delivery vehicle. This topic has been extensively reviewed in Shenk
(1996), and Fields et al. (1996).
1.A.2 Virion Structure
The virus particle is composed ofprotein and DNA; 87% ofthe viral total mass is protein,
the remaining 13% being DNA. Electrophoretic analysis has revealed that the virion contains at
least 11 structural proteins that are designated by Roman numerals. Seven of these structural
proteins (II, III, IlIa, IV, VI, VIII, and IX) are assembled to form the viral capsid which
surrounds the linear double-stranded DNA genome (Figure 1.1) (reviewed in Stewart et al.,
1991).
18
Core Capsid
II D
/////// III TIlIa~
IV
----
II
, VI
-
,
VIII I
IX ~
Figure 1.1: Schematic illustration of an adenovirus particle. Virion polypeptides are indicated by
Roman numerals with the exception of the terminal protein (TP) (reproduced from Stewart et aI.,
1991).
The viral capsid is composed of240 hexons (trimer ofpolypeptide II) and 12 pentons
(pentamer ofpolypeptide III) (Khilko et al., 1990). These penton proteins mark the vertices of
the icosahedron, and from these vertices a fiber protein is projected. The fiber itself is composed
of three molecules ofpolypeptide IV. The amino terminal of the fiber is embedded in the penton
base, while the carboxy-terminus forms the terminal knob. This terminal knob region ofthe fiber
mediates viral attachment to the host cell receptor (Van Oostrum and Burnett, 1985) and is
19
generally respo;Sibfe ofserotypic variation among related groupmgs of adenoviruses. ->The
fiber/penton combination is referred to as a penton capsomere. Six whole hexon capsomeres and
three penton capsomeres form one complete face of the icosahedron.
The remaining structural viral proteins stabilize the viral capsid through associations with
the hexon capsomeres; polypeptide IX stabilize hexon-hexon contacts within facets, polypeptide
IlIa joins hexons from adjacent facets, and polypeptides VI and III seem to playa role in
connecting the core to the viral capsid (Everitt et aI., 1973).
The remaining four virion proteins are located within the core. Proteins V, VII, and X are
attached directly to the viral DNA, packaging and maintaining the integrity of the viral genome.
The final protein associated with the virion particle is the 55 K terminal protein (TP), which is
covalently attached to the 5' end of the viral DNA and plays an important role in viral DNA
replication (Rekosh et al., 1977).
I.A.3 Genome Organization
The double-stranded DNA genome ofthe adenovirus is approximately 26 kb (Turkey
Ad3) to 45 kb (Fowl AdD) in size (8.7-15 Ilm in length) and is divided into 100 map units by
convention (human adenovirus serotype 5, Ad 5, is 35,937 bp and thus one map unit consists of
360bp) (Genbank (January 3, 2003)
<url>http://www.ncbi.nhn.gov/PMGifs/Genomes/10508.html<url>. Accessed January 8,2003).
At each termini of the viral genome lie inverted terminal repeats of 100 to 200 bp in length
(serotype dependent), embedded within each are identical origins of replication. These sequences
act in concert with the TP during viral DNA replication (discussed in Section 1.A.4.3). Adjacent
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to the left invert~d 'terilili1al repeat lies the packaging domam~-These sequences have been shown
to mediate viral genome encapsidation. The sequence of the packaging domain ofAd5 is located
in the left 380bp (Graeble and Hearing, 1997) and is detailed in Figure 1.2.
AT
GGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAtTAAATTTGGa
190 210 230 250
MI MIT
CGTAACCG~TAAGATTTdocCATTTTCGCGGGAAAACTGAATAAGAGGAA6TGAAATCTG)
270 290 310
AN AV AVI AVIl
~TAATTTTdrrGTTACTCATAGCGChTAATATTTGtCTAGGGCCGCGOGGCATTTGA¢CGTTTA)
CGTGGAGACT
330 350 370
Figure 1.2: Nucleotide sequence of the Ad5 packaging domain. Nucleotide numbers are relative
to the left-end terminus. A repeats AI - AVII are circled. (Schmid and Hearing, 1997)
The packaging domain ofAd5 consists of seven functional A repeat units (termed A for
their high AT content) (Schmid and Hearing, 1997).
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EvolutiOii has-selected for viral genes serving similar'functions t6 be arranged mto
transcriptional units; five early and one late. Organization of the adenovirus genome is detailed in
Figure 1.3.
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Figure 1.3: A schematic illustration of the adenovirus type 2 genome and its division into 100 map
units. Early transcripts are indicated by (E), late transcripts are indicated by (L) and bold arrows.
Structural polypeptides are indicated by Roman numerals, non-structural polypeptides are labeled
by (K) (from Broker, 1984).
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The genefic'map of the adenovirus is customarily presented from left to right, the 00/0
position being left and the 100% position being right. The two strands are termed r-strand and 1-
strand (r standing for rightward transcription, I for leftward transcription) and are by convention
represented with the r-strand as the upper strand, and the I-strand as the lower strand. The early
transcriptional units, including early regions (E)l, 2, 3, and 4, are transcribed prior to the onset of
DNA replication. The late transcription region is activated by the major late promoter (MLP), and
generates five families of late mRNAs (Ll to L5) that give rise to viral structural proteins.
Transcription ofElA, ElB, pIX, and E3, and transcription from the MLP, occurs from the r-
strand. E2, IVa2, and E4 are transcribed from the I-strand. Interestingly, the organization of the
viral genome within the viral capsid places most of the viral transcription units into independent
supercoiled domains (Figure 1.1).
1.A.4 Adenovirus Infection and Replication Cycle
The replication cycle of adenoviruses lasts between 20 and 24 hours. It is characterized
by two phases: early (those events occurring prior to DNA replication), and late (those events
occurring after DNA replication) phases. Figure 1.4 shows the relative timing of the major events
that occur during the viral replication cycle.
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Figure 1.4: The timing of major events occurring during the adenovirus replication cycle. The
genes responsible for each event are listed. (All the Virology on the WWW (February16, 1999).
<url>http://www.tulane.edu/f'-Jdmsander/WWW/335/Adenoviruses.html<url>. Accessed
September 10,2001.).
Adenovirus infection commences as the infecting virus comes into contact with the host
cell. The virus particle then penetrates the host cell and eventually makes its way to the nucleus.
Early gene expression quickly ensues, followed by viral DNA replication. With the onset of viral
DNA replication, transcription from the MLP and translation of the late proteins begins. Virus
particles assembled from a precursor pool of structural virion proteins and DNA are then released
as the infected cell is ruptured.
1.A.4.1 Attacliment and Entry
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Attachment of the virus to its' host cell receptor, the coxsakievirus and adenovirus
receptor (CAR) (Bergelson et al., 1997), is mediated by the knob region of the fiber protein
(Devaux et al., 1987). Subsequent internalization of the virus particle is mediated by an
interaction between the penton base protein and a family ofheterodimeric cell surface receptors,
termed integrins. The pentonlavP3 and a V P3 vitronectin-binding integrin (and perhaps other
members of the integrin family) interaction triggers diffusion into clathrin-coated pits, followed by
receptor mediated endocytosis (Wickham et a!., 1993; Varga et al." 1991).
Virus particles release into the cytosol from the endosomes follows, triggered by the acidic
pH of the endosome (Seth et a!., 1984; Svensson et al., 1985). A series ofcapsid uncoating
steps occurs during viral escape from the endosome. The polypeptides composing the viral capsid
sequentially dissociate starting from the vertices (polypeptides IV, IlIa, III, VIII, VI, IX, and II
sequentially). Transport to the nucleus is mediated by microtubule/hexon interaction (Luftig and
Weihing, 1975). The structure of the DNA-protein complex which enters the nucleus has not
been elucidated, but it is known that protein V is removed prior to entry into the nucleus (Greber
et al., 1993).
Viral DNA association with the nuclear matrix through the terminal protein is the final
step of the infection cycle prior to the onset ofearly gene activation (Schaack et a!., 1990). The
process ofadenoviral attachment and entry into the host cell is summarized in Figure 1.5.
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-Endosome
dIsruption
Figure 1.5: Attachment and entry of the adenoviruses to the host cell (reproduced from Barnett et
aI., 2002)
Transcription ofthe early viral genes begins soon after viral DNA entry into the nucleus.
The gene products of these early viral genes play critical roles in creating a cellular environment
conducive to adenoviral replication.
Products ofthe El region (EIA and EIB) not only activate transcription ofother early
viral genes, but also antagonize cellular gene products which maintain the integrity of the cell
cycle. E2 proteins mediate viral DNA replication initiation and polymerization. E3 gene products
code for several proteins which antagonize the host immune response to viral infection. E4 gene
products are also involved with viral DNA replication, and inhibit host cell macromolecule
26
biosynthesis.
Protein IX has been defined as an intermediate early gene, since it is active earlier in the
infection than the late genes. Protein IX is not only a virus structural protein, but is also a
transcriptional activator of several viral and cellular TATA-containing promoters. Protein IX has
also been inferred in the reorganization of the nucleus which accompanies viral transcription
(Rosa-Calatrava et aI., 2001; and references therein).
1.A.4.2 Disruption of Host Cell Cycle Control and the Adenovirus Early
Region 1
The primary actions of the E1 proteins is the induction of cell cycling in infected quiescent
cells and trans-activation ofviral transcription. Creating an environment conducive to viral
replication begins with transcription of the first early gene, E1A. This unit produces five proteins
named for the sedimentation coefficient of their mRNAs: 13S, 12S, lIS, lOS, 98. The 138 and
128 transcripts are synthesized and translated early, while the other transcripts are transcribed late
in the infection. The function of these late transcription units is still unknown (Shenk and Flint,
1991).
Transcriptional activation by the E1A proteins is accomplished primarily through
competition with transcription repressor proteins (specifically the retinoblastoma susceptibility
protein family of transcription repressors) for binding sites on proteins essential for transcription
activation, but also stimulate transcription by binding transcription repressive DNA binding
proteins and stabilizing transcription initiation complex formation. Highly conserved regions in
both the E1A and EIB proteins essential for these protein-protein interactions have been
27
identified (reviewed in Shenk, 1996).
The EIB proteins activate transcription in a similar fashion to the EIA gene products, by
targeting a separate set of transcription factors (specifically p53). In addition to it's role as a
TFIID binding protein, p53 is a sequence-specific DNA binding protein and can stimulate gene
expression in genes whose promoters carry it's response element. Genes whose products arrest
cell cycle progression are stimulated by p53. Thus the EIB 55 K protein both blocks and induces
gene expression through its interactions with p53. In addition, high levels ofpS3 can induce
apoptosis (reviewed in Zambetti and Levine, 1993). The EIB 19 K protein can block apoptosis
through it's association with p53. It has been suggested that this apoptosis block may be due to
the activation ofpS3 repressed cellular survival genes (White et al., 1991).
The EIB 55 K protein also functions in transporting viral mRNAs, and shutting offhost
cell biosynthesis (Babiss et al., 1984).
The protein-protein interactions of the early region 1 gene products not only complex with
their cellular targets increasing viral gene transcription, but strongly alter cellular transcription.
The early region 1 gene products induce dramatic progression of the cell cycle while preventing
apoptosis, and thus foster the generation of an environment conducive to viral replication.
1.A.4.3 Viral DNA Replication and the Adenovirus Early Region 2
The early region 2 ofhuman adenoviruses is comprised of two sub-regions: E2A which
codes for the 72 K DNA binding protein, and E2B which codes for the 140 K DNA polymerase
and the 80 K precursor to the terminal protein. Transcription of the E2 region occurs from two
promoters: early and throughout infection from a promoter at 75 mu, and after DNA replication
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from a promoterat' 72- mli'(Figure 1'-3)..
The 72 K DNA binding protein is required for increased efficiency ofviral DNA
elongation~ host range determination~ assembly of the viral particle~ and binding ofboth single and
double-stranded DNA (Hay and Russell~ 1989).
The E2B derived DNA polymerase is responsible for both the initiation and elongation
steps ofviral DNA replication. In addition to forming pTP-dC:MP (deoxycytidine 5'_
monophosphate), the adenovirus DNA polymerase possesses a 3' to 5' exonuclease activity that
may serve a proof reading function during polymerization. A cellular protein, nuclear factor II~
and the viral template are the final requirements for viral DNA elongation (Hay and Russell,
1989).
The 80 K terminal protein precursor is cleaved by a virally coded 23 K protease to
produce the 55 K terminal protein, though this conversion is not essential for viral DNA
replication. In addition to it's vital role in viral DNA replication, the terminal protein plays a vital
role in early adenovirus infection, anchoring the viral DNA to the nuclear matrix, and qlediating
initiation and enhancing viral transcription (Hay and Russell, 1989).
Accumulation ofa threshold level of these £2 gene products and host cell entry into S
phase allows viral DNA replication to begin. Adenovirus DNA replication is a two stage process:
the first being characterized by protein-primed strand displacement occurring once from either end
of the viral chromosome at the ITRs. During the second stage a complement to the displaced
strand is synthesized through self-circularization and consequent self-priming of the displaced
strand via the ITRs. The formation of the distinctive panhandle structures allows the template to
be recognised by the same replication machinery as double stranded viral DNA (Figure 1.6).
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The 5' lYound- terminal protein (or 80 K pre-terminal"protein) serves as a prime~i for DNA
synthesis initiation and preserves the integrity of the viral chromosome terminus throughout
successive rounds ofDNA replication. The preterminal protein binds the template and is then
complexed with the a-phosphoryl group of dCMP at the P-OH of a serine residue in the
preterminal protein by the E2-encoded polymerase. Following this coupling reaction, the
preterminal protein-dCMP complex serves to prime the template DNA strand for replication
(Lichy et al., 1981).
Ad DNA :BiILding Ilt'OteiD.
TP
OAd.----.POlNucle3.t'~3.CtorI
\
Figure 1.6: Adenovirus DNA replication (All the Virology on the WWW (February 16, 1999).
<url>http://www.tulane.edu/~dmsander/WWW/335/Adenoviruses.html<url>. Accessed
September 10,2001.).
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The process- o~fadenovirus DNA replication continlies· until the host-cell is finally
ruptured or dies (Figure 1.4).
1.A.4.4 Abrogation of the Host Immune Response by the Adenovirus Early
Region 3 and the Virus Associated RNAs
Host immune response to adenovirus infection proceeds in two stages. The first stage is
characterized by damage to lung tissue, the appearance of the cytokines tumor necrosis factor
(TNF) and interleukins 1 and 6, and a diffuse cellular infiltration ofperibrochiolar and alveolar
regions. The later stage consists almost entirely ofan infiltration ofvirus-specific cytotoxic T
lymphocytes (CTL). The adenovirus has evolved several countermeasures to subvert immune
system-mediated destruction of infected cells. The early region 3 gene products and the virus-
associated RNAs (VA RNAs) and other early region proteins mediate these countermeasures
(Ginsberg et al., 1991).
The E3 region codes for nine proteins, five ofwhich (19 K, 14.7 K, 14.5 K, 10.4 K, and
6.7 K) are involved in protecting adenovirus infected cells from immune detection and
destruction.
The 19 K E3 gene product abrogates CTL-mediated virus infected cell destruction by
interfering with the type I major histocompatibility complex class I (MHC class I) antigen
presentation pathway. Through interaction with the MCH class I peptide binding domain, the E3-
19 K proteinfMHC complex is retained in the endoplasmic reticulum. The subsequently reduced
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level of antigen pres~eiltation allows infected cells to evade iiriiriune surveillarice (Burget and
Kvist, 1987).
Both the E3-14.7Kd protein and the complex formed between the £3-14.5 K and E3-10.4
K proteins can prevent cytolysis by tumor necrosis factor a (TNF-a). TNF-a is a cytokine that
can induce lysis ofvirus infected cells and is secreted by activated macrophages and lymphocytes.
This E3-protein complex and the E3-6.7 K protein are required for the down-regulation ofTNF-
related apoptosis-inducing ligand receptors. The E3-6.7 K protein has also been shown to confer
protective effects against calcium flux-induced apoptosis by operating to maintain endoplasmic
reticulum calcium homeostasis (Moise et aI., 2002; and references therein).
The VA RNAs work against the host immune response by providing protection against the
effects of interferon. Interferon inhibits viral replication by inducing protein kinase R (PKR)-
mediated inhibition of protein synthesis in infected cells. Homologous RNA sequences produced
by symmetrical transcription of the viral genome can produce double stranded RNA which is
subsequently bound by two molecules ofprotein kinase R (PKR). Autophosphorylation ofPKR
is required for it's activity and requires two molecules of the enzyme. Phosphorylated PKR
phosphorylates a key subunit required for translation initiation, eukaryotic initiation factor 2 (eIF-
2), thereby inactivating it. The GC-rich, short (approximately 160 bp) VA RNA species are
produced in increasing amounts as the infectious cycle progresses, but are present during the early
stages of infection. The VA RNAs form short hairpin structures which allow only one PKR
molecule to bind, thus inhibiting PKR autophosphorylation, and therefore decreasing both PKR-
mediated eIF-2 phosphorylation, and subsequent translation inhibition (Kitajewski et aI., 1986).
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The E1 gerie'proaucts also pla:y a role in antagonizirig-the host cell iniinune response.
E1A gene products inhibit the anitviral effects of interferon by blocking the activation of
interferon response genes (Reich et al.~ 1988). By virtue of its anti-apoptotic effects~ the EIB-
19Kd gene product also combats host cell immune response by inhibiting TNFa-induced
apoptosis (discussed in section 1A3.2).
1.A.4.5 Early Region 4
Recent advances in the understanding ofE4 gene products at the molecular level have
reveled that these proteins posses an unexpectedly diverse collection of functions which
orchestrate many viral processes (Tauber and Dobner~ 2001; and references therein). E4 proteins
playa role in increasing viral transcription~ viral DNA replication~ shutting off cellular
macromolecular synthesis, and contributing to the oncogenic process.
The £4-17 K protein activates the E2F transcription factor by a cooperative binding
reaction. Two molecules ofthe 17 K protein bind cooperatively bridging the gap between a pair
ofE2F binding sites within the E2 promoter, thus activating E2 transcription and allowing the
viral DNA replication machinery to be assembled (Raychudhuri et al., 1990).
Once DNA replication starts and enough late viral mRNA has accumulated, the transport
of cellular mRNAs to the cytoplasm is blocked by an E4-34 K/El-55 K protein complex. It is
theorized that this complex localizes some nuclear factor vital to mRNA transport out of the
nucleus to sites within the nucleus where viral mRNA replication is concentrated (Omelles and
Shenk, 1991).
1.A.4.6 Caie~'-Gehe Expression, Virus Assembly-and- Release from the-"Cell.
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Adenovirus late gene expression begins with the onset ofDNA replication (Figure 1.4).
The primary transcript of the late coding regions is a single unit approximately 29,000 nucleotides
in length. This transcript is subsequently processed through mRNA splicing to produce at least
18 distinct mRNA species. These late mRNAs have been grouped into five families, Ll to L5,
based on common polyadenylation sites (Figure 1.3). All late viral mRNAs possess a 200-
nucleotide "tripartite leader sequence" which is lacking in secondary structure. It has been
postulated that this lack of secondary structure allows efficient translation ofviral mRNAs
without the need for cellular helicase (which is inactivated late in viral infection) in order to scan
through the mRNA secondary structure for translation initiation sites (Huang and Schneider,
1991 ).
Once translation of the late viral mRNAs has taken place, trimeric hexon capsomeres are
rapidly assembled with the aid of the L4-100 K protein acting as a scaffold protein (Liebowitz and
Horwitz, 1975). Penton capsomeres are assembled from preformed trimeric fiber and pentameric
penton base at a slower rate than the heron capsomere (Horwitz et al., 1969). After their
production, the two capsomeres accumulate in the nucleus where viral assembly occurs.
Virus assembly begins with the formation of empty capsids, followed by a left-end
polarized packaging of the viral DNA into the empty capsid molecule mediated by the packaging
sequence and some collection of as ofyet unidentified proteins. The generation of infectious virus
requires that the L3-encoded viral protease process proteins VI, VII, and VIII, whose cleavages
stabilize the viral particle (reviewed in Philipson, 1984).
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E1B-19Kd 'polyp-eptide and the viral protease mediate- disriIption -of the cytoskeletal
system and consequent rupturing of the host cell and final release of the viral progeny (White and
Cipriani, 1989; Chen et aI., 1993).
1.A.5 Virtues of the Adenovirus System
1.A.6
The accumulation ofknowledge and understanding ofthe replication and lytic cycle of the
adenoviruses has given way to the ability to utilize the adenovirus as a general purpose
mammalian expression vector, and potentially as vectors for gene therapy and vaccination. In
addition to the well understood genetics of the system, the adenovirus possesses a number of
amenities which make it an attractive vehicle for gene delivery. The viral particle is relatively
stable, as is the genome which does not readily undergo rearrangement. Infected cells produce
1,000-10,000 infectious units per cell, and the virus remains in the cell long after maximum
production allowing for easy concentration of stocks (reviewed in Graham and Provoke, 1995).
And finally, several systems for manipulating the genome ofthe adenovirus have been developed.
The following section reviews the current methods available for recombinant adenovirus rescue.
Recombinant Human Adenovirus Deletion/Substitution Virus
Rescue Systems
The development of recombinant adenovirus rescue systems has followed a logical and
systematic path, changing and improving as discoveries in DNA manipulation technology
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applicable to the-cie~atibfi-ofadenovirus vectors have been mad-e: -The list recombinant
adenovirus vectors followed the development of techniques to manipulate DNA in vitro.
Recombinant adenoviruses were originally generated by direct in vitro ligation of insert with viral
DNA using traditional cloning methods (Ballay et a!., 1985; Giraldi et a!., 1990) and
understandably suffered from problems associated with manipulating a large linear genome. Low
virus yield and the inevitable presence of background wild type virus generated by incomplete
viral DNA digestion were among such problems.
Eliminating the difficulty ofdealing with a linear genome was addressed by the
development of large bacterial plasmids carrying a modified Ad genome (Ghosh-Choudhury et al.,
1986) which could be manipulated with traditional cloning techniques. While the use of these
large bacterial plasmids made manipulation easier, the lack of unique restriction enzyme
recognition sites limited the utility of these systems. The discovery that shuttle vectors carrying
only a small portion of the virus genome could be easily manipulated and then fused with the viral
genome by in vivo homologous recombination was, utilized to overcome this hurdle. The smaller
size of the shuttle vectors increased the number ofunique restriction sites available and made the
production ofnovel unique sites routine, thus allowing for the creation of larger deletions and
novel recombinants. Recombination between overlapping sequences in shuttle plasmids (Ghosh-
Choudhury et a!., 1986) or between shuttle plasmid and digested viral DNA (Raj-Ahmad and
Graham, 1986) during transfection into HEK293 helper-cells (Graham et al., 1977) generates a
functional viral genome. This cell line constituitively expresses the Ad5 E1 genes, and thus can
complement E1 deletions in recombinant adenoviruses by supplying the E 1 gene products in
trans. The co-transfection method has been utilized to generated hundreds ofrecombinant Ad
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vectors, and proiOc'61s- arid techniques for the isolation ofE I" andlor E3-d-eletion Ad vectors have
been extensively reviewed in Graham and Prevec (1995).
A substantial time requirement of several months was generally required to produce pure
recombinant virus when utilizing these methods due to the typically laborious in vitro construction
strategies required to insert the exogenous DNA within the shuttle plasmid and the numerous
plaque isolations required to purify the recombinant viral particle.
Even with numerous plaque purifications, generation of replication competent Ad (RCA)
sub-populations can occur via homologous recombination between homologous virus genome and
helper-cell genomic sequences (Lochmiiller et al., 1994; Hehir et aI., 1996). Figure 1.7 illustrates
how recombinant adenovirus vectors are generated and how wild-type virus production can occur
during a typical rescue experiment.
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Viral DNA
Homolgous Recon1binatlon
Shuttle vector DNA
Left-end Ad Sequences Flanking E3 Ad Sequences
A)
Recombinant viral DNA
B) ~ J X Homolgous Recombination
~Left-endAd Sequencesl~~~~~~~~~~~~~~~~~~_
Packaging cell-line genomic DNA
Figure 1.7: A) Schematic representation of recombinant adenovirus generation by homologous
recombination. B) Production of contaminating replication-competent wild-type virus during
recombinant virus rescue.
An important limitation that emerged during early in vivo experiments utilizing
recombinant Ad vectors for transgene delivery was the loss of transgene expression occurring
concurrently with the development ofpathology in the organ expressing the transgene. This
finding was subsequently linked to a virus-specific immune response resulting primarily from the
presence of contaminating RCA in experimental preparations (Yang et aI., 1994; Hermens and
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Verhaagen, 1997).'
Given the damaging effects ofRCA contamination and the virtues of the recombinant
human Ad vectors for the study of basic Ad biology and their potential as gene therapy delivery
systems, research efforts for several years have understandably been directed almost exclusively
towards the elimination of contaminating wild-type virus in recombinant Ad vector preparations.
The first such effort involved modification of the two plasmid in vivo recombination Ad
production system by making use of the packaging constraint imposed upon the viral genome by
the finite size of the viral capsid (Ghosh Choudhury et al., 1987) and utilized a large genomic
plasmid exceeding the viral packaging constraint (McGregory et al., 1988). Wild-type virus
contamination has since been limited or eliminated using a number ofnovel in vitro systems
(Davis et a!., 1998; Mizuguchi and Kay, 1998; Anderson et a!. ,2000), cosmid (Miyake et al.,
1996; Hisanori et al., 1998), E. coli (Chartier et a!., 1996; Crouzet et a!., 1997; He et al., 1998;
Souza and Armentano, 1999; Youil et al., 2001) and S. cerevisiae (Ketner et al., 1994)
recombinational targeting systems, chimeric Ad2/Ad5 constructs (Hehir et a!., 1996), and by in
vitro (Aoki et al., 1999) and in vivo (Hardy et al., 1997; Ng et al., 1999; Ng et al., 2000; ) site-
specific recombinase systems. Novel E1-complementing cell lines have also been generated
(Fallaux et a!., 1998; Ilmer et al., 1996; Kim et a!., 2001) which decrease or eliminate the degree
ofhomology which exists between virus and cell-derived left end Ad sequences.
The need for efficient wild-type free recombinant Ad rescue has certainly been addressed.
However, improvement upon the traditional method of in vitro DNA sub-cloning insertion of
foreign DNA into rescue vectors (which are still required in all of the above mentioned systems)
has been addressed solely by substitution for other in vitro manipulation techniques such as the
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introduction of unique restriction sites (Hisanori et a!., 1998;--MiZUguchi-et al.-, 1998), blunt-end
ligation techniques (Miyake et al., 1996), intron-encoded nucleases (Souza and Armentano,
1999), or multiple cloning sites (Bett et al., 1994; He et al., 1998; Ng et al., 2000).
Traditional DNA sub-cloning by relying on compatible restriction enzyme sites is still a
stumbling block that can lead to labourious linker insertion strategies, or subject the researcher to
lengthy screening processes associated with blunt-end cloning. And the fixed locations of
restriction sites within the plasmids utilized to create the above mentioned systems have dictated
the position(s) of genome manipulation. Furthermore, non-essential sequences essential for the
utility of the above mentioned sequences (such as site-specific recombinase recognition
sequences, or residual multiple cloning site sequences) remain embedded in the rescued viral
genome. The development ofviral gene therapy vectors for human use calls for extremely precise
deletions and additions to the viral genome to maximize efficiency and treatment efficacy. In vivo
ligation strategies are available that are capable of circumventing the limitations of current DNA
manipulation technology.
1.B S. cerevisiae In Vivo Ligation Systems
The ability to subclone, manipulate, and transfer DNA fragments from one plasmid to
another is a central activity in molecular biology. Often the availability ofunique, rare, or even
overabundant restriction sites within final and intermediate plasmid constructs can dictate the
entire direction ofexperimental design. Such situations therefore lead to the undertaking of
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cumbersome, multi-step in vitro cloning experiments to remove, or add, the necessary restriction
enzyme recognition sequences in order to successfully obtain desirable plasmid constructs. The
double strand (ds) break repair system ofS. cerevisiae (recently reviewed in Sung et aI., 1999;
reviewed in Szostak et aI., 1983) offers many unique opportunities for in vivo ligation
experiments which have the potential to circumvent many of these common problems in plasmid
construction and manipulation.
In vivo ligation systems in the yeast S. cerevisiae have the same requirements as most
other plasmid DNA systems in yeast. A selectable marker is required to force transformed yeast
cells to maintain plasmid DNA once they become transformed. Typically the selection agent
employed is some form of auxotrophy. Of equal importance to the selectable marker is the
corresponding recessive and non-reverting chromosomal mutation that causes the auxotrophy.
Sequences for efficient replication 8:nd. mitotic segregation (2 Jlm circle origin of replication and
partitioning sequences, or chromosomal replication signal sequence, ARS, and centromere, CEN)
are the other requirement of a yeast plasmid system. Usually, the yeast plasmid systems are
coupled to bacterial sequences which allow efficient shuttling between yeast and bacteria (ie/
bacterial origin of replication and selectable marker). In the yeast such DNA is maintained in a
circular topology, and linearized plasmid DNA lacking telomere sequences will fail to replicate
and partition effectively. When linear fragments which possess overlapping homologous
sequences are co-transformed into the yeast, they can undergo homologous mitotic recombination
through the dominant double strand break repair pathway regenerating the circular topology of
the plasmid (Mezard and Nicolas, 1994).
These principles were utilized in gene disruption using PCR products in S. cerevisiae
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(Lorenz et al., f'995~-Mariivasakam et al., 1995) prior to the -advent of current in vivo ligation
protocols. Two forms of in vivo ligation strategies have been developed utilizing similar
methodo10gies.
In both two-part plasmid construction (Oldenburg et al., 1997) and linker-mediated
plasmid repair by homologous recombination (Raymond et al., 1999) an acceptor fragment
(containing the necessary yeast and bacterial replication origins and selectable markers) is
linearized using restriction endonucleases to provide broken ended DNA as substrate for
homologous recombination. The fragment to be inserted into the acceptor backbone is termed the
donor. Regions ofhomology between the acceptor and donor are introduced via 5' overhang
regions in oligonucleotide primers utilized to'PCR amplify the donor fragment (in the case of two-
part plasmid construction by homologous recombination, Figure 1.8A), or by PCR amplified
linker regions which possess homology to both the acceptor and donor fragments (linker-assisted
homologous recombination, Figure 1.8B). Acceptor and donor, or acceptor and donor and
linkers are transformed into the yeast and successful in vivo ligation manifests itself as a positive
yeast transformante Isolation of the plasmid from the transformed yeast cells and back-
transformation into E. coli effectively filters out yeast transformants resulting from any integration
events which might have occurred during the transformation process.
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Figure 1.8: A) Two-part plasmid construction using homologous recombination. B) Linker-
assisted plasmid construction using homologous recombination.
Minimum lengths of sequence homology required for successful in vivo cloning have been
defined (Hua et al., 1997). Also, the use of partially digested acceptor (Miletti and Leibowitz,
2000) coupled with selectable marker shuftling (Miletti and Leibowitz, 2000; Gunyuzlu et aI.,
2001), and PCR independent recombinational cloning strategies using single stranded DNA
oligonucleotides in place ofPCR generated linkers (DeMarini et aI., 2001) have vastly expanded
the number of in vivo ligation protocol options available to the researcher.
In vivo ligation techniques have been successfully adapted to simplify large plasmid
manipulation (Miletti and Leibowitz, 2000). Adaptation of these techniques to adenovirus
research could subvert many problems common to the various aspects of this field.
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I.e Project Objectives
The manipulation of large plasmid (>10 kb) systems amplifies problems common
to traditional cloning strategies. Unique or rare restriction enzyme recognition sequences
are uncommon and very rarely occur in opportunistic locations. 1,1aking site-specific
deletions and insertions in larger plasmids consequently leads to multiple step cloning
procedures that are often limited by time consuming linker insertions or lovv efficiency
bllint-end cloning strategies. Manipulation of the adenovirus genome and the genomes of
other viruses as bacterial plasmids are systems that typify such situations.
In order to determine if recombinational cloning techniques would be capable of
circumventing the difficulties common to manipulation of the larger plasmids associated
with adenovirus research, we chose the human adenovirus E I-deletion rescue plasmid
system, used for the production ofE1-deletion recombinant adenovirus vectors, as a
model system.
Bett et ale (1994) produced a generalized rescue vector containing a multiple
cloning site in place ofnucleotides 359 through 3522 of the adenovirus type 5 genome.
Due to the large deletion generated, this plasmid became the progenitor of virtually all
E1-deletion rescue systems to follow. The creation of this vector required complex
partial and double digestion ofmultiple pDNAs with multiple enzymes and complex
linker insertion strategies. Additional steps would then still have been required to make
the desired insertions into the multiple cloning site. We will attempt to create a similar
deletion (nucleotides 384 through 3514), while simultaneously inserting a common
reporter gene encoding the Green Fluorescent Protein (Figure 1.9). This deletiol1 leaves
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the entire adenovirus packaging region (Figure 1.2) and the adenovirus protein IX
promoter intact.
To this end, a I'Rp acceptor plasmid will be generated and the adenovirus E1
rescue vector system will be utilized to examine the location requirements ofDNA ds
breakage relative to the site of linker generated homology during in vivo ligation
reactions, and the ability of in vivo ligation to generate the large deletions commonly
required during manipulation of the adenovirus genome. We will use the Green
Fluorescent Protein (GFP) gene from the ~flII/4flIII fragment ofpEGFP-N1 (BD
Bioscience Clonetech) as our donor fragment to be inserted into the acceptor molecule.
Expression of this gene will then be used as an indication of the reliability of the
recombinational cloning reaction. Homology between these two DNA sequences
required for successful recombinational cloning will be generated by PCR amplification
of the appropiate acceptor plasmid sequences using primers containing 5' overhang
encoded homology to the donor fragment. The DNA fragments involved in the
recombinational cloning reaction and the expected product are outlined in Figure 1.9.
Ifit is determined that in vivo ligation can foster the creation of large deletions in
the acceptor plasmid during recombinational cloning, selectable marker deletion during
recombinational cloning will be assessed as a method for decreasing screening workload.
CMV promoter
1-5.89
GFP
679-1398
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SV40 polyA
.1552-7, 1581~6
LtIVL
Acceptor
Donor GFP
3514-3757
RtIVL
E1A and E1B regions
1-103
ITR
194-380
packaging domain
384/1
Homologous
Recombination
3525-3555
Protein IXpromoter
1610/3514
Product GFP IXp IX
Figure 1.9: Diagram of recombinationaI cloning reaction utilized in the assessment of
homologous recombination-mediated adenovirus rescue vector manipulation.
Recombination between the donor fragment containing the Green Fluorescent Protein
(GFP) gene from the AjlIVAjlIII fragment ofpEGFP-N1 (BD Bioscience Clonetech) and
the acceptor fragment containing a 22 bp truncation of the left 5,788 bp of the human
adenovirus type 5 contained in the plasmid pXC38 (Bautista et al., 1991) catalyzed by
PCR-generated linker regions (LtIVL and RtIVL) that supply homology between donor and
acceptor fragments is depicted by crosses between the fragments. Adenovirus and pEGFP-
N1 sequences are numbered according to Genbank Accession X02996 or BD Bioscience
Clonetech convention, respectively. Features within the fragments are numbered in
accordance with the adenovirus (italics) or pEGFP-N1 (normal type) regions that they
encode, and borders between donor and acceptor sequences in the recombination product
are numbered accordingly.
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2. MaterIafs~~-an(f Methods
2A) Recombinant DNA Techniques
Note that recombinant DNA techniques were carried out according to Sambrook et af.
(1989) unless otherwise stated.
2.A.I Bacterial Strains
Escherichia coli strain DH5a was utilized for the cloning and amplification ofpEGPP-NI,
and all pUC19 and pXC plasmid derivatives. E. coli DH5a possesses the following genotype: P-,
<1>80, t::>lacZ, dM15, d( lacZYA- argF), U169, deoR, recAI, endAI, hsdRI7(rk-, mk+),phoA,
supE44, thi- 1, A-, gryA96, relAI.
2.A.2 Propagation and Maintenance ofBacterial cultures
E. coli was grown in sterile Luria-Bertani broth (LB; 1% bacto-tryptone, 0.5% bacto-
yeast extract, 1% NaCI, 4 N NaOH to pH 7.0) overnight at 37°C in a shaker incubator. Cells
were frozen in 50% glycerol (3 ml 50% glycerol/7 ml cell culture) at - 80°C for long term storage.
Short term storage ofE. coli cultures (grown on solid (LB, 20% bacto- agar w/v) or in liquid LB
media) was possible if the cultures were stored at 4°C.
2.A.3 Preparation of Competent E. coli Cells
Cells from a single colony ofE. coli, isolated from a single cell (achieved using dilution
plating on LB plates) was picked and grown overnight in 2 mL LB. Incubation was at 37°C in a
shaker water bath unless otherwise indicated. The other halfof the same colony was inoculated
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into 2 mL ofLB~fo'riIfied with 100 ~g/mL ampicillin. lfno groWth occuITed-m the ampicillin-
containing tube, 2 mL ofovernight culture was then inoculated into 200 ml LB and allowed to
grow to mid- log phase (O.D' sSG == 0.45- 0.55). The cells were then placed on ice before being
centrifuged for 10 minutes at 3,500 rpm and 4°C in a Beckman Avanti J-25 centrifuge (JA-14
head). The supernatant was removed and the cells were resuspended by gentle inversion in 25 mL
of ice cold, sterile transformation buffer (75 mM CaCI2, 5 mM Tris, pH 7.6). The cell suspension
was incubated from 4-16 hours at O°C before being centrifuged for 10 minutes at 3500 rpm and
4°C. The supernatant was discarded and the remaining cells resuspended by gentle inversion in 4
mL ice cold, sterile transformation solution and incubated at O°C for 30 minutes. The competent
cell suspension was then mixed with 50% glycerol (3 mL 50% glycerol! 7 mL cell culture),
partitioned into 150 ilL portions and subsequently stored at -80°C.
2.A.4 Transformation of Competent E. coli
One Ilg ofplasmid DNA suspended in TE buffer [1 mM ethylene diamine tetra-acetic acid
(EDTA), 10 mM TrisHCI (pH 7.5), pH 7.0] was inoculated into 150 ilL ofpreviously frozen,
competent E. coli. The mixture was subsequently incubated at O°C for 30 minutes, with light
agitation every ten minutes. The DNA- competent cell mixture was then heat-shocked at 42°C
for 45 seconds, and placed back on ice for 2 minutes. Nine hundred ilL ofLB was then added
and the mixture incubated at 37°C for 40 minutes. Seventy five to one hundred fifty ilL aliquots
were then plated on LB plates containing the appropriate bacterial selection agent, kanamycin for
pEGFP-Nl (50 Ilg/mL), and ampicillin (100 Ilg/mL) in all other cases.
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2.A.5 Modified Mllll-c-pieparation ofPlasmid DNA (pDNA)
Single colonies growing on 100 J..lg/mL ampicillin LB plates were picked and grown
individually overnight in 3 mL of ampicillin-containing liquid LB media. One and one-half mL of
culture was then transferred to a sterile Eppendorftube and centrifuged at 12,500 rpm for 10- 30
seconds in a Dupont Sorvall MC12V desktop centrifuge (this model was used throughout this
procedure). The media was then removed by vacuum aspiration and the cell pellets resuspended
in 200 ~L of sterile resuspension solution (50 mM Tris.HCI (pH 7.5), 10 mM EDTA, 10 ~g/mL
RNAse A) per tube by vortexing. Two hundred J..lL cell lysis solution (1 % w/v sodium dodecyl
sulphate (SDS), 0.2 M NaOH) was added to each tube and mixed by inversion for 1 minute. Two
hundred ~L of sterile neutralization solution (1.32 M potassium acetate (KAce), pH 4.8) was
added to each tube and the tubes mixed by inversion. The contents of each tube were then
centrifuged at 12500 rpm for 10 minutes at room temperature. The supernatant was then
transferred to a new Eppendorftube and two volumes (300 ~L) of isopropanol was added to
each tube. The tubes were then centrifuged at 12,500 rpm at room temperature for 10 minutes,
the supernatant was poured off: and the tubes allowed to dry. The pDNA pellet was then
resuspended in 100 ~L ofTE buffer.
2.A.6 Restriction Enzyme Digestion ofPlasmid DNA
Procedures involving specific restriction enzymes were carried out in accordance with the
manufacturers guidelines (New England Biolabs). All restriction enzyme digestions were carried
out overnight (approximately 13- 15 hours) at 37°C.
Typically, 5 J.1L ofpDNA in TE buffer, 2 J.1L of the recommended 10 X restriction
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enzyme buffer (and~2-p,L-'of10 X bovine serum albumen (BSA)),-1 unit/llg DNA ofre-striction
enzyme, and double distilled water comprising the remaining 20 ilL reaction mixture volume.
Reaction mixtures which were to be used for "Gene Clean®" band excision from agarose
gels (procedure to be outlined in Materials and Methods section 2A.14) had a final volume or 30
ilL; 15 ilL ofpDNA in TE buffer, 3 ilL of the recommended 10 X restriction enzyme buffer
with 3 ilL of 10 X BSA, 1 unit/llg DNA ofrestriction enzyme, and double distilled water
comprising the remaining reaction mixture volume.
2.A.7 Partial Restriction Enzyme Digestion ofpDNA
Partial restriction enzyme digestion was carried out according to the method ofParker et
al., 1977. Typically, Ilg amounts ofplasmid DNA were matched with equal unit values of the
appropriate restriction enzyme, buffer (and BSA ifnecessary) in the presence of varying amounts
ofethidium bromide (EtBr)(O.1 to 10 Ilg) in 100 ilL reaction volumes. Reactions were incubated
at 37°C and 10 ilL aliquots were taken at multiples of equal time intervals (usually 15 s or 30s).
The reactions were stopped by the addition of 5 ilL of loading buffer to each aliquot. Agarose
gel electrophoresis and visualization with EtBr was then utilized to visualize the optimal time
interval for which to incubate the reaction. A full 100 ilL reaction was then performed and
stopped by the addition of 50 ilL of loading buffer. The desired partially digested fragment was
then purified from the agarose gel after electrophoresis and visualization with EtBr.
2.A.8 Agarose Gel Electrophoresis
DNA fragments resulting from restriction enzyme digestion ofpDNA were separated and
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visualized using agarose gel electrophoresis. Agarose gels were made by dissolving 0.9% (w/v)
agarose in TAE buffer (40 mMTris, 20 mM acetic acid, 1 mM EDTA, pH 8.0) by heating in a
microwave oven. The gel was allowed to solidify in a tape-d gel tray with an appropriately sized
gel comb inserted into the gel. The gel comb used was dictated by the volume ofthe restriction
enzyme digestion reaction mixture and by the purpose for the DNA fragment separation. If the
pDNA was digested for visualization offragment size (only 20 JlL total volume) a gel comb
creating approximately 25 JlL wells was used. If the pDNA was digested for band excision and
band recovery by "Gene Cleaning" (30 JlL total volume) a gel comb creating approximately 55
JlL wells was used.)
Once the gel had solidified, the tape and gel comb were removed and the gel placed in an
appropriately sized gel box containing EtBr (0.15 Jlg/ mL) TAE buffer. Loading buffer (0.05%
bromophenol blue, 20% glycerol, 2% SDS) was mixed with (1/6 ratio ofbuffer/ reaction mixture)
the reaction mixture prior to loading into the wells. Five JlL ofNorgen Nl DNA ladder was also
added to one of the wells allowing estimation ofpDNA fragment size. Plasmid DNA fragments
were separated at 1-10 V/cm, viewed under UV light and then photographed using a Bio-Rad
Gel-Doc 1000 and Multi Analyst Software.
2.A.9 Large Scale pDNA Isolation
Frozen cells (or cells remaining from modified mini- preparation ofpDNA) were
inoculated into 2 mL of ampicillin LB broth and grown overnight in a 37°C shaker bath. One mL
ofovernight culture was transferred to 500 mL ofampicillin LB broth and allowed to grow at
37°C for 14-15 hours in a shaker- incubator. The culture was then centrifuged at 5,000 rpm for
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5- 10 minutes at--4°C'-miri'IEC PR-6000 centrifuge. The supernatant was poured off and the cells
resuspended in 25 mL ofresuspension solution and allowed to sit for 35 minutes. The cell
resuspension was then transferred to centrifuging bottles along with 25 mL of lysis solution (100/0
SDS w/v, 0.2M NaOH) and the mixture was mixed by gentle inversion for 5 minutes. Twenty
five mL ofneutralization solution (2M KAc, pH 4.8) was added, and mixed in by inversion. The
bottles were then centrifuged at 12,000 rpm for 16 minutes at 4°C in a Beckman Avanti J-25
centrifuge (JA-14 head). This centrifuge was used for all 12,000 rpm centrifugations. The
supernatant was then filtered through a sterile coffee filter.
To facilitate banding in cesium chloride gradients, 25mL 3M sodium acetate (3M NaAc,
pH 7) and 150mL of ice-cold absolute ethanol was added to the supernatant, and the mixture was
then centrifuged at 12000 rpm for 15 minutes at 4°C. The supernatant was removed by vacuum
aspiration, and the pellet resuspended in 16 mL ofTE buffer.
Plasmid DNA resuspended in TE buffer was then examined for correct restriction
fragment banding patterns by agarose gel electrophoresis to verify the presence of the desired
plasmid prior to cesium chloride (CsCI) banding.
The density ofthe resuspended pDNA was adjusted to 1.57-1.59 g/ mL using CsCl.
Density was determined by solution weight. Five hundred ilL (0.15 Ilg/mL) EtBr/l0 mL
pDNA/CsCl. mixture was added and the density adjusted back to 1.57-1.59 g/mL. (Note: Once
concentrated EtBr solution had been added~ the plasmid DNA solution container was covered in
aluminum foil at all times to prevent exposure to light.) The mixture was centrifuged at 60,000
rpm for 22 hours at O°C in a Beckman Optima XL-lOOK ultracentrifuge using an NVT-65 rotor.
After centrifugation, the upper relaxed circular and linear pDNA band was allowed to leak
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out of the centrifuge tube by creating a small hole in the centrifuge tube with a 16 gauge needle~
just below the nicked pDNA band. The supercoiled pDNA band was then withdrawn from the
centrifuge tube using a 16 gauge needle and syringe.
EtBr extraction from the isolated supercoiled pDNA was facilitated by repeated mixing of
equal volumes ofDNA suspension with CsCI saturated isoamyl alcohol. Once the isoamyl alcohol
had been added and mixed with the pDNA solution by inversion, the solution was centrifuged at
500 rpm for 2 minutes in an International Equipment Company Centra-8R centrifuge prior to
removal of the EtBr containing isoamyl alcohol layer removal. This process was repeated until no
EtBr remained in solution.
The pDNA solution was transferred into boiled, clip-sealed dialysis tubing, and incubated
in 2L sterile~ 4°C SSC buffer (0.15 M NaCI, 0.015 M sodium citrate) to facilitate removal of any
remaining isoamyl alcohol and CsCI. Dialysis was carried out in the buffer for two hours before
the buffer was changed. The pDNA solution was then dialysed for two additional 12 hour
exchanges in SSC buffer.
After dialysis against SSC buffer, purified pDNA was dispensed into sterile Eppendorf
tubes for storage at 4°C.
2.A.I0 Determination ofpDNA Concentration
The concentration ofpDNA was determined spectrophotometrically. Plasmid DNA was
diluted in TE buffer. The ATI UNICAM UVNis spectrometer was then blanked using TE buffer
and the absorbance values of the diluted pDNA solutions were measured at 280 nm and 260 nm
wavelength light using Vision software version 3.00. The following formula,
[PDNA] (A260)(dilution factor)(50)
1000
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was then applied.
Only pDNA solutions yielding A260/ A280 values of greater than 1.6 were utilized for yeast
transformation experiments.
2.A.ll Heat Inactivation ofEnzymes
It was at times necessary to inactivate certain restriction enzymes (or shrimp alkaline
phosphatase) prior to use of the reaction mixture in ligations or transformations. Heating reaction
mixtures to 65°C for 20 minutes inactivated all enzymes utilized during the course of these
experiments.
2.12 Shrimp Alkaline Phosphatase Treatment ofRestriction Enzyme Digested pDNA
In order to suppress recircularization of restriction enzyme digested pDNA upon ligation,
shrimp alkaline phosphatase (SAP) was used to remove the 5' phosphate groups from the pDNA
fragments. Reactions were carried out in accordance with the manufacturers guidelines
(Boehringer- Mannheim). A typical SAP reaction mixture was as follows: 25 J.1L heat inactivated
restriction enzyme digestion reaction mixture, 2 J.1L SAP, 5 J.1L lOX SAP buffer, 18 ~L double
distilled water.
SAP reaction mixtures were allowed to incubate for 45 minutes at 37°C, before heat
inactivation as described in the Materials and Methods section 3A.l o.
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2.A.13 Klenow Treatment ofDigested pDNA
In order to create blunt-end DNA fragments from restriction enzyme digested pDNA, the
Klenow fragment ofE. coli DNA polymerase I (NEB ©) was utilized to fill in 5' overhangs
generated by cohesive end generating restriction enzymes. .Typically, 1 f..Lg ofdigested, plasmid
DNA was incubated with 2.5 units ofKlenow fragment in the presence of200 JlM dNTP and the
appropriate volume of lOX EcoPol reaction buffer for 15 minutes at room temperature.
Reactions were stopped by phenol:chlorofonn:isoamyl alcohol extraction.
2.A.14 Excision ofRestriction Enzyme Digested pDNA Fragments from Agarose Gels
Individual bands ofpDNA fragments were excised and purified directly from agarose gels
using the Bio 101 Gene Clean Kit. The kit removes salts, RNA, proteins, and EtBr from DNA.
A sterile, sharp razor was used to cut the appropriate band from the agarose gel under UV
light. The band was placed into a previously weighed Eppendorf tube and the tube weighed
again. Three volumes NaI/weight of agarose gel (mL/g) were then added to the tube and the
tube was incubated at 45°C for 5 minutes. Five JlL ofvortexed glassmilk was then added to the
mixture. The mixture was then incubated at room temperature and mixed every minute for 5
minutes. The mixture was then centrifuged for 5 seconds at 12,500 rpm in a Dupont Sorvall
Me12V desktop centrifuge (this centrifuge was used throughout this procedure) and the
supernatant removed by aspiration. The pellet was resuspended by pipetting in 300 f.lL ofNew
Wash, and then centrifuged for 5 seconds at 12500 rpms. This was repeated three times before
the pellet was resuspended in 25 ilL ofdouble distilled water. The resuspension was then
incubated at 55°C for 5 minutes before centrifuging at 12,500 rpm for 30 seconds. Twenty J-!L of
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supernatant confaiiringC-the purified pDNA fragment was removed-and placed-into a sterile
Eppendorftube. The remaining 3-5 uL of supematant was subjected to agarose gel
electrophoresis in order to verify that the correct fragment had been isolated.
2.A.15 Ligation ofRestriction Enzyme Digested pDNA Fragments
Bacteriophage T4 DNA ligase was used to catalyse ligation of separate DNA fragments.
Reaction mixtures were set up according to the manufacturers guidelines (MBI Fermentas). A
typical reaction mixture contained the following reactants; 15 ilL heat-inactivated restriction
enzyme digestion mixture containing the smaller insert pDNA fragment, 5 JlL heat-inactivated
restriction enzyme digestion mixture containing the larger pDNA fragment, 4 JlL 10 X T4 DNA
ligase reaction buffer, 1 JlL T4 DNA ligase, 15 JlL double distilled water.
Ligations of restriction enzyme digested pDNA fragments were carried out in an ice box
at 4°C overnight (14-15 hours). The reaction mixture was then utilized to transform E. coli
DH5a.
2.A.16 Phenol:Choloroform:lsoamyl Alcohol Extraction ofDNA
An equal volumes of25:24:1 (v:v:v) phenol:cWoroform:isoamyl alcohol (PCI) capped
with 8-hydroxy-quinoline and the solution containing the DNA of interest were mixed in an
Eppendorftube followed by vigorous vortexing until an emulsion had formed. The tube was then
centrifuged at 12,500 rpm for 5 minutes at room temperature. In cases when it was necessary to
do so, the PCI extraction was repeated until the white protein precipitate separating the aqueous
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and organic phases was no longer present. The aqueous layer containing DNA was then removed
and transferred to a sterile Eppendorftube with an equal volume ofwater saturated chloroform.
The tube was vortexed for one minute and centrifuged at 12,500 rpm for one minute. The
aqueous layer was then removed. The sodium acetate concentration of this solution was adjusted
so that a final concentration of 0.3 Mwould be reached with 3 M sodium acetate (pH 7.0), and 2
volumes of ice cold ethanol were added. The solution was stored at -20°C for one hour before
centrifugation at 12,500 rpm for 10 minutes. The supernatant was then poured off and all
remnants aspirated taking care not to disrupt the pellet. The pellet was then washed with 80%
ethanol and centrifuged at 12,500 rpm for 10 minutes. The supernatant was then poured off and
all remnants aspirated taking care not to disrupt the pellet. The pellet was dried at 37°C for 5
minutes before resuspension in an appropriate volume ofTE buffer.
2.A.17 Polymerase Chain Reaction
All polymerase chain reactions were carried out in 50 ilL reaction volumes in DiaMed Lab
Supply Inc. PCR tubes in an ERICOMP singleblock Easycycler thermocycler. Typical reactions
contained 5 ilL lOX PCR reaction buffer without MgCl2 (MBI Fermentas), 0.01-1 Ilg template
DNA, 15 pmoles forward and reverse primers (generated by SigmaGenoSys Inc.), 200 IlM dNTP
mixture (New England Biolabs), 2 mM MgCl2 (MBI Fermentas), and 2.5 units ofTaq polymerase
(New England Biolabs). All reactions entailed a 5 minute initial denaturation step at 94°C,
followed by 35 rounds of 1 minute denaturation at 94°C, 1 minute annealing at 47°C, and 1
minute extension at 72°C, followed by a final 5 minute extension at 72°C.
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2.A.18 Propagat1on~aiiaMaintenanc'e ofS. cerevisiae Cultures-
The haploid Saccharomyces cerevisiae laboratory strain ofJY128 was utilized during the
course of this research. S. cerevisiae JY128 carries the following auxotrophic and genetic
markers: Matcx, ura3-52, lys2-801, ade2-101, trpl-d63, his3d200, leu2dl, g1n3, KANR •
Yeast were allowed to grow to stationary phase in sterile YPD broth (1 % bacto- yeast
extract w/v, 2% bacto- peptone w/v, 2% dextrose w/v) overnight at 30°C in a shaker incubator.
Culture stocks were. stored on solid YPD plates (YPD, 2% bacto- agar w/v) or in liquid YPD
media at 4°C. For long term storage ofyeast cells, stationary phase liquid cultures were adjusted
to 15% glycerol and frozen at -80°C.
During transformation experiments, synthetic medium (0.67 % Bacto-yeast nitrogen base
without amino acids, 2% dextrose, 1 M sorbitol, 20 mg/L Adenine sulfate, 20 mg/L Uracil, 20
mg/L L-Tryptophan, 20 mg/L L-Histidine-HC1, 20 mg/L L-Methionine, 30 mg/L L-Leucine, 30
mg/L L-Lysine-HCI, 100 mg/L L-Glutamic acid, in the case of solid medium 2% w/v bacto-agar)
was utilized. Selective medium was made by omission of the amino acid coinciding with the
auxotrophy being complemented. Plates utilized to select for loss ofthe URA3 marker were made
according to Boeke et aI., 1984. Briefly, a 2g/L concentrate of 5-fluoro-orotic acid was filter
sterilized, and mixed with a 2-fold sterile concentrate ofuracil fortified selective media. Plates
were then poured from the mixture and allowed to solidify at room temperature overnight.
2.A.19 Replica Plating of Yeast Cultures
Yeast colonies growing at suitable sizes and· densities (less than 150 colonies per plate)
were transferred between selective media plates using sterile velvet sheets reinforced by a circular
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wooden block (of'stightiy' lesser diaIneter than that of the plates). - For plates- with larger colony
densities, selective media plates bearing two different auxotrophies were paired, and sectioned
identically. Sterile toothpicks were used to transfer the colony under investigation first to the
plate with the untested auxotrophy, then to the selective plate for which complementation had
previously been verified. The plates were then incubated for 3-5 days before examination.
2.A.20 Preparation ofElectrocompetent Yeast Cells
Electrocompetent yeast cells were prepared according to a modified version of the
protocol described in Becker and Guarente, 1991.
One hundred mL ofYPD in a 500-millilitre flask was inocculated with a suitable aliquot
from a stationary phase, yeast culture to give an O.D.6oo of 1.4 -1.5 the next morning. It was
determined through growth curve analysis that the inflection point of the logarithmic growth
phase occurred within this O.D. range for S. cerevisiae strain JY128. The culture was grown
overnight at 30°C with vigorous shaking.
The next morning the culture was centrifuged at 3,000 rpm at 4°C for 5 minutes. The
supernatant was poured off: and the cell pellet was resuspended in 100 ml of sterile, ice-cold
dH20 by shaking the centrifuge bottles. The cell resuspension was then pelleted again, and
resuspended in 100 ml of ice-cold dH20 and pelleted for a third time. Once again the supernatant
was discarded, the cell pellet was resuspended in 50 ml of sterile, ice-cold 1 M sorbitol, and the
cell resuspension was again centrifuged. The supernatant was poured off and the cell pellet was
resuspended in 0.1 ml of ice-cold 1 M sorbitol with a 200 JlI micropipette. All centrifugation
steps were carried out in an International Equipment Company Centra-8R centrifuge.
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2.A.21 Electroporation ofElectrocompetent Yeast Cells
Electroporation of electrocompetent yeast cells was carried out according to the method
ofBecker and Guarente, 1991.
Fifty III aliquots ofelectrocompetent yeast cells were aliquoted into ice-chilled, sterile
Eppendorftubes containing no more than 5 ul total ofDNA. The sample was mixed using a 200
III micropipettor and then transferred to a 0.2-cm Bio Rad electroporation cuvette. The mixture
was tapped to the bottom of the electroporation chamber, and allowed to incubate on ice for
approximately 5 minutes. The sample was then pulsed at 1.5 kV, 25 mF, 200 Q in a Bio Rad
Gene Pulser II Electroporation System with Pulse Controller ®. Immediately after the pulse, one
ml of ice-cold, sterile 1 M sorbitol was added to the sample using a sterile micropipette. Aliquots
of the electroporated cell suspension and IO-fold, IOO-fold, and IOOO-foid dilutions were then
plated by spreading on selective plates containing 1 M sorbitol.
2.A.22 Mini- Preparation ofYeast pDNA
Single colony positive yeast transfonnants were inoculated into 2 mL of selective liquid
medium and grown overnight to stationary phase in a 30°C shaker- incubator. One and one-half
mL ofthe overnight culture was transferred to a sterile Eppendorftube and centrifuged at 12,500
rpm at room temperature for 5 seconds in a Dupont Sorvall MC12V.desktop centrifuge (this
centrifuge was used throughout this procedure). The supernatant was then poured off: and the
pellet disrupted by briefvortexing. Alternatively, entire plates oftransfonnants were isolated
simultaneously by plate washing with 10 mL ofselective liquid medium. The cell suspension was
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then repeatedly centrifUged and poured off until the entire re"suspension had been pelleied. The
pellet was then disrupted by briefvortexing. To this yeast cell resuspension, 100 f.!L ofbreaking
buffer (1% SDS, 0.5% Triton-X 100,100 mMNaCI, 10 mM Tris.HCI), 100 ilL 25:24:1 (v:v:v)
phenol:chloroform:isoamyl alcohol, and 0.2 g of acid washed glass beads (Sigma Aldreich Co.)
(prepared by one hour soaking in nitric acid, followed by extensive washing with distilled water
and overnight drying at 80°C) was added, followed by vigorous vortexing for at least 2 minutes.
The tube was then centrifuged at 12,500 rpm for 5 minutes at room temperature. The aqueous
layer containing yeast pDNA was then removed and transferred to a sterile Eppendorf tube with
an equal volume ofwater saturated chloroform. The tube was vortexed for one minute and
centrifuged at 12,500 rpm for one minute. The aqueous layer was then removed. The sodium
acetate concentration of this solution was adjusted to 0.3 M with 3 M sodium acetate (pH 7.0),
and 2 volumes of ice cold ethanol were added. The DNA precipitation was stored at -20oe for
one hour, before centrifugation at 12,500 rpm for 10 minutes. The supernatant was then poured
off and all remnants aspirated taking care not to disrupt the pellet. The pellet was then washed
with 80% ethanol and centrifuged at 12,500 rpm for 10 minutes. Again, the supernatant was
then poured offand all remnants aspirated taking care not to disrupt the pellet. The pellet was
dried at 37°C for 5 minutes before resuspension in 10-30 f.!L ofTE buffer. One halfof this
resuspension was subsequently utilized to transform competent E. coli.
2.A.23 In Vivo Ligation Reaction Protocol
All in vivo ligation experiments were carried out according to previously published
protocols (Raymond et al., 1999).
61
Typically, acceptor fragment was prepared as follows: restriction enzyme linearized
acceptor plasmid was PCI extracted twice, followed by one extraction with water saturated
chloroform. DNA in the aqueous layer was then precipitated and resuspended in 5-10 ilL of TE
buffer. When a partial digest was required to linearize the acceptor, the acceptor was digested as
described in section 2.A.7 and isolated from agarose gels as described in section 2.A.I4. In both
cases, the fragment concentration was judged by comparing band density against DNA standards
of known concentration after agarose gel electrophoresis and visualization with EtBr under UV
light. The resuspended linearized acceptor was then adjusted to a concentration of 0.1 Ilg/IlL
with TE buffer.
The donor fragment was prepared by isolating the I,697bp AflII/AflIII fragment of
pEGFP-NI (BD Biosciences Clonetech®) from agarose gels as described in section 2.A.I4.
Typically, it was necessary to pool several isolations to achieve the desired final concentration of
1 Ilg/IlL. Several isolations were pooled in one Eppendorftube and the DNA precipitated. The
resuspended linearized acceptor was then adjusted to a concentration of 1 Ilg/IlL with TE buffer.
The polymerase chain reaction protocol used to amplify linker DNAs (named RtIVL and
LtIVL) containing homology to both the donor and acceptor fragments is detailed in section
2.A.I7. Isolation and analysis of linker DNA after PCR amplification are detailed in Results
sections 3.4 and 3.5. Each linker was resuspended at a final concentration of 1 Ilg/IlL.
During in vivo ligation reactions 0.1 Ilg ofacceptor fragment (1 ilL of 0.1 Ilg/IlL
resuspension), 1 Ilg of donor fragment (1 ilL of 1 Ilg/IlL resuspension), and 1 Ilg ofRtIVL and
1 Ilg LtIVL linker DNA (1 ilL ofeach 1 Ilg/IlL resuspension) were mixed and cooled on ice in
Eppendorf tubes prior to the addition ofelectrocompetent yeast cells (preparation detailed in
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section 2.A.20),~erectroporationand plating (detailed in section 2:A.21).-
All in vivo ligation experiments were performed in triplicate. The total volume ofeach
electroporation was plated as three equal portions on separate selective media plates.
Transformants growing on the selective plates were counted and analysed 5-7 days later.
2.B) Mammalian Cell Culture Techniques
Note that unless otherwise stated, all mammalian cell culture techniques were performed
as indicated in Graham and Prevec (1995).
2.B.l Ad 5 Transformed Human Embryonic Kidney Cell (293 Cell) Maintenance
Human Embryonic Kidney 293 cells (Microbix Inc., ATCC CRL 1573) were maintained
as monolayer cultures at 37°C in a humid 5% CO2 atmosphere in a Napco 5200 CO2 incubator.
Medium utilized was MEM (Gibco BRL) supplemented with 0.225 % (w/v) sodium bicarbonate
(GibcoBRL ), 0.292 microg/mL L-Glutamine, 5% v/v heat-inactivated fetal bovine serum (FBS)
and 5% heat-inactivated horse serum (HS) (CanSera International, Inc.), and fortified with 1%
Antibiotic-Antimycotic (10,000 units/mL penicillin G sodium, 25 Ilg/mL amphotericin B, and
10,000 units/mL streptomycin sulphate, Gibco BRL).
All tissue culture dishes and tubes with the exception of6-well plates (Costar) were
obtained from Sarstedt.
All cell manipulations were carried out in a Baker Company, Inc. SterilGARD Hood after
20 minute UV sterilization periods. Aseptic technique was utilized in all cell manipulations. Cells
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were observed usmg-iTELAVAL :3 microscope (Carl Zesus-Jena).
2.B.2 293 Cell Passaging
Nearly confluent 293 cell monolayers were passaged by using sterile saline citrate (15 mM
sodium citrate, 135 mM potassium chloride) to facilitate cell lifting from culture dishes. Used
medium was aspirated from the plate, and the cells washed once with 5 mL saline citrate. The
wash was then aspirated and 3 mL saline citrate was applied to the monolayer. The cells were
then allowed to incubate at 37°C until cell rounding and lifting was observed. The cells were
dislodged by gentle tapping of the culture dish. Seven mL ofnew medium was then added to the
cell suspension and the cells were separated by gentle tituration. Five mL ofthe cell suspension
was then added to a new culture dish, and was adjusted to a final volume of20 mL with
additional culture medium. The cells were then allowed to reattach overnight at 37°C.
2.B.3 293 Cell Freezing and Thawing
Frozen 293 cell cultures were maintained in liquid nitrogen storage. Used medium was
aspirated from the plates containing nearly confluent 293 cell monolayers, and the cells washed
once with 5 mL saline citrate. The wash was then aspirated and 3 mL saline citrate was applied to
the monolayer. The cells were then allowed to incubate at 37°C until cell rounding and lifting
were observed. The cells were dislodged by gental tapping of the culture dish. Seven mL of
culture medium was then added to the cell suspension and the total cell suspension transferred to
a 12 mL conical tube. The cells were then pelleted at room temperature by centrifugation at 800
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rpm for 5 minutes'iii an-International Equipment Company Centra-8R centrifuge. The~medium
was then poured off and the cells resuspended in 4 mL freezing medium (90% FBS, 10% dimethyl
sulphoxide) by gentle inversion. The cell suspension was then aliquoted into 2 mL cryotubes and
incubated at -80°C overnight. The cells were then transferred to liquid nitrogen storage.
Frozen cell cultures were thawed by incubation in a 37°C water bath and added to a
culture dish containing pre-warmed 37°C medium. The cells were allowed to attach for 6-12
hours before the medium was changed to remove unattached cells.
2.B.4 Transfection of293 cells Using ExGen 500 In Vitro Transfection Reagent ®.
Transfection using this procedure was carried out according to the supplier's
recommendations (MBl Fermentas). Briefly, 293 cells were plated in 6-well culture dishes one
day prior to transfection so that cells would be 50-80% confluent at the time oftransfection. The
medium in the 6-well plates was changed 3 hours prior to transfection. For each transfection, 1-5
Ilg mixtures ofpDNA were diluted in 270 III sterile 150 mM NaCI. The ExGen 500 transfection
reagent (3.3 flL per 1 flg pDNA) was added to the pDNA solutions and immediately vortexed.
The ExGen reagent was then allowed to complex with the pDNA for 10 minutes. The
transfection solution was then mixed by gently pipetting before being added to one well ofa 6-
well plate. The plates were agitated gently before being incubated at 37°C.
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2.B.5 Visualiz'atioTI -o-f-Green Fluorescent Protein Expression" - -
Forty eight hours after transfection, medium was aspirated from transfected 293 cell
monolayers prior to Green Fluorescent Protein (GFP) expression visualization. GFP expression
was visualized using a Leitz Diaplan Microscope outfitted with a fluoroscein filter set (excitement
wavelength of488 nm) and photographed using a Wild Leitz Wild MPS 46 Photo Autoformat
system. Photographs were taken with Kodak Gold 400 speed film. The film was manually
exposed for between 1 and 6 seconds.
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3. Results
3.1 Construction of the YRpXC38 Acceptor Vector
For any in vivo ligation reaction to be successful, an acceptor vector with the
appropriate backbone sequences for replication and selection in S. cerevisiae must be
present in the reaction. In order to create an acceptor plasmid with the appropriate yeast
replication and selectable marker sequences the 1,456 bp TRP1lARS EcoRI fragment of
YRp7 (Tschumper and Carbon, 1980) was inserted into the unique EcoRI site of the
bacterial cloning vector pXC38 (Bautista et aI., 1991) as indicated in Figure 3.1. The
TRP1 gene ofS. cerevisiae encodes N-(5'-phosphoribosyl)-anthranilate isomerase, a vital
enzyme in the tryptophan amino acid synthesis pathway (Jones and Fink, 1982). The
ARS sequence of the 1,456 bp TRPIIARS EcoRlfragment ofYRp7 encodes as.
cerevisiae chromosomal origin ofreplication (Tschumper and Carbon, 1980). pXC38
contains the appropriate bacterial origin ofreplication and selectable marker for plasmid
maintenance and propagation in E. coli and contains a 22 bp truncation of the left 5,788
bp of the adenovirus type 5 genome which encodes one of the inverted terminal repeats,
the packaging domain, the early region 1, and the protein IX gene.
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Figure 3.1: Construction Strategy for YRpXC38. The 1,456 bp TRPllARS EcoRI
positioning values for the restriction sites used to verify YRpXC38 conformation are
given in brackets and are relative to the unique EcoRI digestion site ofpXC38.
3.2 Restriction Enzyme Confirmation ofYRpXC38 construction
Transformation of competent E. coli DH5a with overnight ligation reactions of
purified 1,456 bp TRP1lARS EcoRI fragment from YRp7 and shrimp alkaline
phosphatase treated EcoRI digested pXC38 generated ampicillin-resistant bacterial
colonies. EcoRI screening ofpDNA isolated from forty-two such ampicillin-resistant
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bacterial colonies revealed that only one contained a pXC38 clone harboring the 1,456 bp
TRPllARS tragmenf(as illustrated in lane 7 ofFigure 3·.-2). "By convention, this plasmid
was termed YRpXC38. In order to determine the orientation of the TRPllARS insert in
the YRpXC38 plasmid restriction fragment banding pattern analysis was performed
(Figure 3.2). The predicted sizes of restriction fragments from the parent plasmids YRp7
and pXC38 and both possible YRpXC38 conformations are listed in Table 3.1.
Table 3.1: Predicted sizes ofrestriction fragments from parent plasmids YRp7 and
pXC38 and both possible YRpXC38 constructs. ND indicates no predicted digestion
products.
Restriction Fragment Size (bp)
Plasmid Restriction Enzyme
KpnI EcoRI BglII HindIII XbaI
YRp7 ND 4.,361 5,817 5171 5.,817
1,456 646
pXC38 9,553 9,553 9,553 9,553 9,553
YRpXC38 (A) 1,1007 9,553 6,764 7,525 9.,419
1,454 4,243 3,482 1,588
YRpXC38 (B) 1,1007 9,553 7,012 7,299 8,335
1,454 3,995 3,708 2,672
: -=.•.•. - .':'-.• '-
KpnI EcoRI BglII HindIII XbaI
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1,456bp
10kb
7.5
5.1
4.54
3.45
1.9
0.92
0.67
0.54
M Cl C2 YR Cl C2 YR Cl C2 YR Cl C2 YR Cl C2 YR
Figure 3.2: 1% agarose gel showing restriction fragment banding patterns ofparental
plasmids pXC38 (C1) and YRp7 (C2), and the YRpXC38 construct (Y) generated by
insertion of the TR~l/ARS EcoRI fragment ofYRp7 into the unique EcoRI site of
pXC38. Each plasmid was digested with restriction endonucleases KpnI, EcoRI, Bgl!-!,
HindII!, or XbaI. Marker lane is indicated by M, and sizes of marker bands are indicated
(in Kb). The 1,456 bp TRP1/ARS fragment is indicated by an arrow.
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Comparison of the values for predicted restriction fragment sizes for YRpXC38
conformation (A}trom Table 3.1 with the banding patterns observed in Figure 3.2~·
demonstrated that the TRP1IARS fragment was inserted such that the distance between
the two XbaI recognition sequences in YRpXC38 was minimized. This conformation is
illustrated in Figure 3.1.
3.3 Analysis ofS. cerevisiae and E. coli Replication Origin and Selectable
Markers in YRpXC38.
YRpXC38 isolated from ampicillin-resistant E. coli DH5a was banded by CsCl2
density gradient centrifugation and was utilized to transform S. cerevisiae strain JY128
byelectroporation. Electroporation experiments generated an average of5.6 x 104 trp+
transformants/Jlg pDNA, and thus verified the functionality of the ARS and TRP1
sequences in YRpXC38.
Transformation ofcompetent E. coli DH5a with total plate isolation oftrp+ S.
cerevisiae transformant pDNA generated an average of 50 +1- 20 ampicillin-resistant E.
coli colonies per transformation. Restriction endonuclease digestion ofpDNA isolated
from the ampicillin-resistant E. coli transformants yielded identical banding patterns to
that ofdigested YRpXC38 (Figure 3.3).
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patterns observed in Figure 3.3 are consistent with those were observed in Figure 3.1 and
described in Table-3.1~ and the o'bservedNcoI fragments'-ln-F'igure 3.3B are consistent
with those predicted for such a digestion (7,759 bp, 1,785 bp, and 1,463 bp fragments
generated via three recognition sites at YRpXC38 positions 2269, 3732, and 5517).
Taken together these data offered substantial proof that positive trp+ yeast transformants
indeed resulted from transformation of the yeast by YRpXC38.
3.4 Construction of the LtIVL and RtIVL In Vivo Ligation Linkers
Linker DNA providing homology between the donor and acceptor fragments was
generated via PCR amplification of acceptor sequences in YRpXC38 with primers
containing 5' overhangs with homology to donor fragment sequences (Gunyuzla et al.,
2001). Linker LtIVL contained homology to bases 152 through 384 ofthe Ad5 genome
fused to the first forty bases of the CMV promoter driving transcription of the GFP
coding sequence in pEGFP-N1 (Figure 1.9). Linker RtIVL contained homology to bases
1570 to 1610 ofthe pEGFP-N1 plasmid (this region encompasses 32 bases of the 3' end
of the GFP mRNA plus an extra eight bases of the pEGFP plasmid) fused to bases 3514
through 3757 ofthe Ad5 genome (Figure 1.9). The primer sequences and the regions
amplified in the PCR reaction are detailed in Figure 3.4.
A)
ARS1fTRP1
SacII(414)· - -
EccR I (I)
//
HpaI(1637)
KpnI(2115)
AdS Xhol-C
AjlII(3596)
SacII(3708)
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B)
C)
SacII(5711)
YRpXC38
LtIVLFl(l52-170) 11007 bp ~LF3 (1570-1610,
~••••••• - •••• •4.~~1-~~~
............. . .....
LtI~ RtIVL~(3738-3757)
(366-384, 1-40)
LtIVLF1:
LtIVLR2:
RtIVLF3:
RtIVLR4:
5'cgacggatgtggcaaaag
5'atgaactaatgaccccgtaattgattact
attaataacta gtctccacgtaaacggtc
5'aaatttcacaaataaagcatttttttcac
tgcattctagt ctgaaatgtgtgggcgtg
5'tcgtaggtcaaggtagtag
Figure 3.4: A) Relative positions of linearizing restriction sites used during in vivo
ligation experiments. B) PCR amplification scheme for in vivo ligation linker
generation. The dark horizontal lines represent adenovirus sequences within the plasmid.
Hatched lines represent template sequences for linker amplification. Adenovirus
sequence and pEGFP-Nl nucleotide position values are labeled in normal and bold,
respectively. C) Sequences ofprimers used in linker amplification (homology to
pEGFP-Nl and Ad5 sequences indicated by bold and normal type, respectively).
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3.5 Analysis ofLtIVL and RtIVL In Vivo Ligation Linkers
Following linker peR amplification, the size and concentration of the amplified
linkers were determined by agarose gel electrophoresis. The expected sizes of the LtIVL
and RtIVL linkers are 273 bp and 285 bp, respectively (Section 3.4). Both LtIVL and
RtIVL migrated as expected and appear to be of the proper size, as seen in Figure 3.5.
M RtIVL LtIVL
500 bp
400 bp
300 bp
250 bp
200 bp
Figure 3.5: 2% agarose gel showing in vivo ligation linkers LtIVL and RtIVL after
ethanol-precipitation and resuspension in TE buffer. Marker lane is indicated by M, and
sizes of marker fragments are given (in bp).
Linker amplification yields were typically between 6-10 l-lg per reaction.
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3.6 S. cerevisiae JY128 Exponential Growth Inflexion Point
Determination
Three 100 mL sterile YPD culture flasks were inoculated sequentially with 20 J.lL
of stationary phaseS. cerevisiae JY128 broth cultures at 15 minute intervals.
Measurements OD600 were taken at one hour intervals after the initial inoculation and
were used to determine the OD600 at which this S. cerevisiae strain grows at its
maximum rate. The inflection point of the exponential growth phase occurred at
approximately OD600 =1.49. Yeast cells were consequently harvested between
OD600=1.4 and 1.45 for preparation ofall electrocompetent cells.
3.7 Initial In Vivo Ligation Experiments
It has previously been demonstrated that use ofblunt-end restriction sites
significantly reduces numbers ofbackground transformants generated by resealing of
cohesive-end linearized acceptor by S. cerevisiae during in vivo ligation (Raymond et al.,
1999). Consequently, in an effort to decrease subsequent screening workload blunt-end
HpaI-digested YRpXC38 acceptor (Figure 3.4) was the first acceptor substrate utilized
during in vivo ligation reactions.
Co-introduction ofHpaI-linearized YRpXC38 acceptor, 1,657 bp AjlII/AjlIII
donor fragment, and LtIVL and RtIVL PCR amplified linkers into S. cerevisiae by
electroporation resulted in an average of 172 (+/-22) trp+ colonies (see Figure 3.4 for
YRpXC38 HpaI site location and Figure 1.9 for predicted recombination reaction).
However, as indicated by Figure 3.6, control reactions lacking either donor fragment
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(A+L) or linker DNA (A+D) or both (A) were not significantly different from in vivo
ligation reactions-containing Hpal-linearized acceptor, donor, and 1iTIker DNA (A+L+D).
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170
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12
193.5
+/-
8
153
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75
172
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200
trp+
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per 150
electroporation
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A+L A+D A A+L+D
Figure 3.6: Mean and standard deviation summary of in vivo ligation reactions using
HpaI digested YRpXC38 acceptor. L, D, and A represent 1Jlg ofeach linker (LtIVL and
RtILV), 1Jlg of 1,697 bp AjlII/AjlIII pEGFP-N1 donor fragment, and 0.1 Jlg HpaI digested
YRpXC38 acceptor, respectively. Control reactions were carried out simultaneously by
omitting the donor (A+L), the linkers (A+D), or both (A).
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Literature values indicate that a successful in vivo ligation reaction is typically
marked by a large increase in positive transformant generation with 80-95% being of the
desired conformation (Raymond et al., 1999; Hua et al., 1997). Comparison of in vivo
ligation reaction (A+L+D) and control reaction (A+L, A+D) efficiencies by t-test
analysis revealed that in vivo ligation reactions did not differ from controls.
3.8 Initial In Vivo Ligation Transformant Analysis
In order to assess the structure ofthe recombinant plasmids generated by initial
in vivo ligation experiments, back transformations to competent E. coli were performed
using pDNA isolated from total plate isolations oftrp+ positive yeast transformants
generated during these experiments. Forty ampicillin-resistant colonies were produced.
Restriction fragment banding patterns ofpDNA isolated from these colonies revealed that
initial in vivo ligation experiments did not generate the plasmid of the conformation
predicted in Figure 1.9, but did generate two other populations ofrecombinant plasmids.
These plasmids were determined to be acceptor molecules containing deletions ofeither
1.1 kb or 2.6-2.7 kb. These deletions were mapped by comparing restriction enzyme
fragment banding patterns ofthe recombinant plasmids to those of the YRpXC38
acceptor (Figure 3.7).
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--- 2.6-2.7 kb deletion
-::';-. _ "';....:. - -;
1.1-1.2 kb
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1.lkbp deletion mapping
SacII KpnI EcoRI/KpnI
MC ECECE
1234567
BglII(3335) SacII(3834)
AjlII (3533)
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SacII BglII AjlII
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Figure 3.7: A) Locations of restriction sites and predicted deletions within adenovirus
sequences in YRpXC38 generated during initial in vivo ligation reactions. B) Restriction
fragment banding patterns of 1.1-1.2 kb and 2.6-2.7 kb deletion recombinants (E)
generated during in vivo ligation experiments utilizing HpaI digested YRpXC38 acceptor
and YRpXC38 control plasmid (C). Note that SacII digesion was incomplete.
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Ninety-five percent (38 of40) of the recombinant plasmids isolated from
ampicillin-resistarifE.-'coli possessed an approximately f.-l-kb- deletion. This deletion
was flanked by SacII (414) and KpnI (2115) as demonstrated by the retention of those
sites in the recombinant plasmid (Figure 3.7B), lanes 3 and 5, respectively). Figures 3.4
and 3.7A show the location of these sites in YRpXC38. The approximate size of the
deletion was determined by comparing the EcoRl/KpnI 2,115 bp fragment (Figure 3.7B,
lanes 6) and the 1 kb EcoRI/KpnI fragment released from the recombinant (Figure 3.7B,
lane 7).
The remaining 2 recombinant plasmids analyzed possessed a 2.6-2.7 kb deletion
flanked by SacII (414) and extending beyond BglII (3391), but not beyond AjlII (3596).
Figure 3.7B demonstrates the recombinant and YRpXC38 possess the same number of
SacII sites (Figure 3.7, lanes 8 and 9) andAjlII sites (Figure 3.7B, lanes 12 and 13),
however BglII (3391) is absent in the recombinant (Figure 3.7B, lanes 10 and 11). The
approximate size of the deletion was determined by comparing the 3,476 bp SacII
fragment from YRpXC38 (Figure 3.7B, lane 9) with the approximately 800 bp SacII
fragment from the recombinant (Figure 3.7B, lane 8).
3.9 Second In Vivo Ligation Experiment
Published results indicate that the ratio of the desired in vivo ligation product to
other recombinants should be much higher than ratios observed during initial in vivo
ligation experiments (Raymond et al., 1999; Hua et al., 1997). One possible reason for
the lack of successful in vivo homologous recombination could have been the distance
between the left and right regions of linker-generated homology and the HpaI site utilized
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to linearize the acceptor. HpaI digestion of the acceptor generated 1,197 bp and 1,936 bp
extension between the left and right regions of linker-generated homology and the ds
break, respectively (Figure 3.4). It is likely that such a distance was too great for the
yeast recombination machinery to successfully mediate homologous recombination. Ds
DNA break repair utilizes 3' single stranded (ss) DNA tails arising through ds break
processing (Figure 3.8) as substrate for homologous recombination reactions. The
maximum size of such ss DNA tails observed to this point has been approximately 1kb
(reviewed in Sung et al., 1999).
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DS DNA Break
•
Repair DNA Synthesis
Resolution of intermediates
Ligation•
~ Unwinding
Helicase
Rad50/Mrell/Xrs2
SS tail arises
throughDSB
end processing
Scission by endonuclease activity
______ 5' 3'
------....,,/ Rad51 (RPA)
>
Strand invasion
Figure 3.8: Current model of double strand DNA break repair in S. cerevisiae. Repair is
initiated by the processing of the free ds DNA end by a three enzyme complex,
Rad50/MreII/Xrs2, producing a ss DNA molecule with a free 3' end. The ss DNA is then
complexed by Rad51, stimulated by the ss DNA binding factor RPA, to form a ss
DNA/protein filament. The Rad51/ssDNA complex invades homologous ds DNA duplex
substrate with which the ds break is repaired. Resolution of recombination intermediates
results in an unbroken DNA molecule.
A unique AjlII site occurs at nucleotide position 3596 in the acceptor (Figure
3.4). This site falls 225 bp withill the rightward region of linker-generated homology.
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Given the size of the linker regions and the location of such a ds DNA break, it was
hypothesized thailiiiearization ofYRpXC38 at this site wo~ld provide ~ accepto~ which
would serve as sufficient substrate to promote homologous recombination. To test this
hypothesis, initial in vivo ligation experiments were repeated using AjlII digested
acceptor.
Co-transformation with AjlII-linearized acceptor, donor fragment, and LtIVL
and RtIVL PCR amplified linkers into S. cerevisiae resulted in an average of 11,000 (+/-
1,300) trp+ colonies, approximately 1.S-fold more colonies than control reactions lacking
either donor (A+L) or linker DNA (A+D) and approximately 2.2-fold more colonies than
control reactions lacking both donor and linker DNA (A) (Figure 3.9).
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Figure 3.9: Mean and standard deviation summary of in vivo ligation reactions using
AjlII digested YRpXC38 acceptor. L, D, and A represent 1f.lg of each linker (LtIVL and
RtILV), IJ.!g of 1,697 bpAjlII/AjlIII pEGFP-NI donor fragment, and O.lf.lgAjlII digested
YRpXC38 acceptor, respectively. Control reactions were carried out simultaneously by
omitting the donor (A+L), the linkers (A+D), or both (A).
Control reactions lacking donor (A+L) or linker DNA (A+D) or both (A) did not
differ significantly from one another by Student's t-test analysis. However, a significant
difference between control (A+L, A+D) and in vivo ligation (A+L+D) reactions was
observed (P=O.05).
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3.1 0 Analysis of Second In Vivo Ligation Transfonnants
In order to assess the structure of the recombinant plasmids generated by
secondary in vivo ligation trials, back transformations of competent E. coli were
performed using pDNA isolated from total plate isolations oftrp+ yeast transformants.
Seventy ampicillin-resistant colonies were produced. EcoRI restriction fragment banding
patterns ofpDNA isolated from 67 ofthese colonies were identical to that of the
acceptor. The remaining three plasmids possessed banding patterns predicted for
successful in vivo ligation recombinants (Figure 1.9 and Figure 3:10B). Restriction
fragment banding patterns of the recombinant plasmid is compared to that of the
YRpXC38 parental plasmid in Figure 3.10.
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B)
Expected Restriction Enzymes
Fragment
Lengths (bp) AjlII SacII BamHI HpaI EcoRI
YRpXC38 11007 5877,3476,1654 ND 11007 9551, 1456
YRpXC-EGFP 9484 5877,1654,1276,677 9484 9484 7013, 1456, 1015
Figure 3.10: A) 1% agarose gel showing restriction fragment banding patterns of in vivo
ligation generated recombinant (R) pDNA and parental YRpXC38 (C) digested with
AflII, SacI!, BamHI, HpaI, or EcoRI. B) Predicted AjlII, EcoRI, SacII, BamHI, and HpaI
digestion products ofYRpXC38 and the predicted YRpXC-EGFP. ND refers to no
predicted digestion products.
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Comparison of the predicted banding patterns with those observed in Figure
3: 10 demonstrates "that in vivo ligation utilizing AflII digested YRpxc38 generated the
desired recombinant and that no detectable errors resulting from the in vivo ligation
reaction could be detected using restriction enzyme screening. AflII, BamHI, and HpaI
digests of the recombinant plasmid produced 9.5 kb fragments, the expected size of the
recombinant plasmid. The recombinant plasmid contained one more SacII site than the
YRpXC38 parent molecule and contained the same unique AflII site. When compared,
these digests indicated that the leftward and rightward regions undergoing homologous
recombination retained restriction sites within these regions. Comparison of the EcoRI
digests demonstrated an extra EcoRI site present in the recombinant. Comparison of the
BamHI digests demonstrated the presence of a unique BamHI site in the recombinant that
was not present in the parent plasmid. Taken together these digests revealed that the
donor fragment was complete within the acceptor backbone (as predicted by Figure 1.9).
3.11 Sequence Analysis of Junction Regions in YRpXC-EGFP
Because of the error rate associated with Taq DNA polymerase (2.85 x 10-4
base insertions, NEB ® 2002-2003 Catalog and Technical Reference) the linker regions
incorporated into the final recombinant plasmid were the only sequences amplified by
PCR and thus contained the greatest risk ofpossessing single base errors. In order to
verify the integrity of the left-end and right-end junctions undergoing linker-assisted
homologous recombination, dideoxy sequencing reactions were performed and results
provided by Norgen Biotek Corp. The expected sequences of the recombinants are
displayed in Figure 3.11.
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Left-end Junction Region: Ad5 151-384 II pEGFP-Nll-40
151 gcgacggatg tggcaaaagt gacgtttttg gtgtgcgccg gtgtacacag gaagtgacaa
211 ttttcgcgcg gttttaggcg gatgttgtag taaatttggg cgtaaccgag taagatttgg
271 ccattttcgc gggaaaactg aataagagga agtgaaatct gaataatttt gtgttactca
331 tagcgcgtaa tatttgtcta gggccgcggg gactttgacc gtttacgtgg agac II
1 tagttattaa tagtaatcaa ttacgggg.:!:c attagttcat
Right-end Junction Region: complementary sequence to Ad5 3760-3514 II pEGFP-Nl1610-1570
3760 gtctcgtagg tcaaggtagt agagtttgcg ggcaggacgg ggcgaccatc aatgctggag
3700 cccatcacat tctgacgcac cccggcccat gggggcatgc gcgttgtcaa atatgagctc
3640 acaatgcttc catcaaacga gttggtgctc atggcggcgg cggctgctgc aaaacagata
3580 caaaactaca taagaccccc accttatata ttctttccca cccttaagcc acgcccacac
3520 attcag ./ /
1610 actagaatgc agtgaaaaaa atgctttatt tgtgaaattt
Figure 3.11: Expected sequences of left-end and right-end regions undergoing linker-
assisted homologous recombination. Regular type indicates expected acceptor fragment-
derived sequences, bold type indicates expected donor fragment-derived sequences.
Position 29 in the right-end junction region was the only sequence abnormality observed
and is underlined.
Ofthe three recombinants isolated, one recombinant (isolate 4.4) possessed a
single thymine base deletion at position 29 of the CMV promoter in the left-end region of
linker-assisted homologous recombination. Recombinant 7.1 contained no detectable
sequence abnormalities and was subsequently termed YRpXC-GFP. YRpXC-GFP was
subsequently used for all mammalian cell transfection experiments.
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3.12 Green Fluorescent Protein Expression in 293 Cells
In order to confirm that homologous recombination events during in vivo
ligation had not altered reporter gene or other vital expression sequences, YRpXC-EGFP
was transfected into HEK 293 cells. Green Fluorescent Protein fluorescence was
observed from transfected 293 cell monolayers exposed to 488 nm wavelength light at 48
hours after transfection (Figure 3.12).
Figure 3.12: Green Fluorescent Protein fluorescence in YRpXC-EGFP transfected 293
cell monolayers visualized by exposure to 488 nm wavelength light.
It was not possible to quantify transfection efficiency due to the techniques
required to examine GFP fluorescence. Expression of the GFP from YRpXC-EGFP after
transfection into 293 cells verifies that in vivo ligation reactions did not alter the function
of the GFP coding or expression sequences.
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3.13 Analysis of In Vivo Ligation Utilizing Klenow-Treated AjlII digested
YRpXC38.
It was demonstrated that the use of acceptor plasmid linearized with cohesive-
end generating restriction enzymes during in vivo ligation reactions allowed the
regeneration of the acceptor plasmid during in vivo ligation reactions (96% ofback-
transformed ampicillin-resistant bacterial colonies harbored YRpXC38 acceptor). It -has
previously been demonstrated that the use ofblunt-end restriction sites significantly
reduces background yeast transformant numbers during in vivo ligation by preventing
acceptor plasmid reformation by ligation ofcohesive ends, thus making more substrate
available for processing by the ds DNA break repair machinery (Raymond et al., 1999).
Klenow treatment of the cohesive end digested plasmid vector prior to
subsequent ligation and bacterial transformation has been demonstrated to vastly reduce
transformation efficiency (New England Biolabs © Inc. Catalog and Technical
Reference, 2002-2003). It was hypothesized that sufficient Klenow treatment of the
cohesive ends would decrease acceptor plasmid reformation and resultant background
yeast transformant numbers during in vivo ligation as well, effectively mimicking the use
of blunt end digested acceptor. The observation that digestion of the acceptor withAjlIl
(which moved the site ofds DNA breakage within the rightward region of linker
generated homology) pr9vided substrate sufficient to participate in the predicted
homologous recombination reaction (Figure 1.9) prompted the generation of blunt-end
digested acceptor fromAjlIl digested acceptor using the Klenow fragment ofE. coli DNA
polymerase I.
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The duration ofKlenow fill-in ofAflII 5' overhang fill-in necessary to mimic
blunt-end YRpXC38 acceptor digestion (similar to HpaI restriction of the YRpXC38
acceptor) was examined. Even after a 40 minute Klenow treatment (15 minute
incubation recommended by the manufacturer, NEB ©), electroporation ofS. cerevisiae
JY128 with equivalent amounts (0.1 Jlg) ofKlenow-treated AflII digested YRpXC38
generated 1.6-fold more trp+ transfonnants than did electroporation with the HpaI
digested YRpXC38 acceptor. (Table 3.2).
Table 3.2: Mean and standard deviation oftrp+ transformants generated after
electroporation with 0.1 Jlg AflII digested YRpXC38 which was Klenow treated for
different durations.
Klenow reaction duration (min)
(HpaI digestion
10
20
25
30
35
40
Mean +/- SD trp+ transformants
153 +/- 7.5)
504 +/- 30
412 +/- 28
230 +/- 45
250 +/- 11
246+/-21
241 +/- 19
Klenow treatment vastly decreased the numbers oftrp+ transformants (from
Figure 3.9, 5100 +/- 400 trp+ transfonnants whenAflII digested YRpXC38 is used to
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transform S. cerevisiae JY128) Klenow treatment of any duration could not decrease trp+
- -.- ~
transformant numbers to values attained when using HpaI digested vector. Perhaps a
small population ofmolecules retained cohesive ends despite the treatment. A 40 minute
Klenow incubation was utilized for subsequent experiments.
Co-transformation ofAjlII digested Klenow-treated YRpXC38 acceptor, donor
fragment, and LtIVL and RtIVL PCR amplified linkers into S. cerevisiae by
electroporation resulted in an average of450 (+/-30) trp+ colonies, approximately 2-fold
more colonies than control reactions lacking donor fragment (A+L) or control reactions
lacking both donor and linker DNA (A) and approximately 1.7-fold more colonies than
control reactions lacking linker DNA (A+D) (Figure 3.13). Control (A+L, A+D) and
experimental (A+L+D) groups differed significantly by t-test analysis (P=0.05).
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Figure 3.13: Mean and standard deviation summary ofknockout in vivo ligation
reactions using AflII digested Klenow-treated YRpXC38 acceptor. L, D, and A represent
1Jlg of each linker (LtIVL and RtILV), 1J.!g of 1,697 bp AflIIIAflIII pEGFP-N1 donor
fragment, and 0.1 Jlg AflII digested Klenow-treated YRpXC38 acceptor, respectively.
Control reactions were carried out simultaneously by omitting the donor (A+L), the
linkers (A+D), or both (A).
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Total plate isolations ofplasmid DNA from trp+ transformants generated during
these in vivo ligation experiments were back-transformed into competent E. coli. Plasmid
DNA from 11 ampicillin-resistant colonies was analyzed by Ncol digestion (Figure 3.14).
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Figure 3.14: 1% agarose gel showing 12 Ncol digested in vivo ligation recombinants
generated using AflII digested Klenow-treated YRpXC38 (Lanes 1-11). YRpXC-GFP
control Ncol digest (C) and marker DNA (M) were included.
Nine of the eleven isolated colonies possessed the expected conformation.
YRpXC-GFP (9,482 bp) possesses four NeoI restriction sites at positions 741, 1058,
2207, and 3992. These sites generate NcoIRE fragments 317 bp, 1,149 bp, 1,785 bp, and
6,231 bp in length. Since earlier recombinant plasmid sequencing and GFP expression
analysis had demonstrated the fidelity of in vivo plasmid construction, no further
characterization of recombinant plasmids was performed.
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As was the case when HpaI digested acceptor was used (blunt end digested
acceptor) a deletlo-n recombinant resulting from intramolecular recombination within the
acceptor was observed (lane 1) but was not characterized further.
Isolate 3 was subsequently determined to be supercoiled DNA ofpUC19 (MBI
Ferrnentas Inc.), which possesses no Nco! sites. Back transformation into E. coli was
utilized and it is possible that pUC19 cross contamination from other experiments in the
laboratory could have occurred.
3.14 YRpETE Construction Strategy
Klenow treatment ofcohesive end digested acceptor is capable of effectively
decreasing regeneration of acceptor plasmid during in vivo ligation, however the reaction
products must be isolated and analyzed at the pDNA level in order to determine which
transforrnant yeast will harbor the recombinant plasmid of interest. This represents a
significant investment in both time and effort. In order to circumvent this pDNA analysis
a system to enable identifying yeast colonies harboring exclusively recombinant plasmid
by examination ofyeast colony phenotype was developed.
It was demonstrated that in vivo ligation reactions are capable of deleting large
segments ofDNA (over 3.1 kb during secondary in vivo ligation reactions) from acceptor
molecules. If the acceptor DNA sequences being deleted during an in vivo ligation
reaction encoded some form ofyeast selectable marker, deletion of that DNA would
manifest itself as an observable change in S. cerevisiae phenotype. Such a change in
phenotype could then be used to distinguish between transformants harboring
recombinant or parental plasmid.
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In order to assess the ability of such a selectable marker "knockout" in vivo
ligation strategy~fo-~decrease screening workload a second yeast selectable-marker, ~URA3,
was inserted into a region of the acceptor that would be deleted during a successful in
vivo ligation reaction. Briefly, the URA3 gene from pYES2 (BD Biosciences Clonetech,
kindly provided by Dr. D. Inglis, Cool Climate Oenology and Viticulture Institute, Brock
University) was PCR amplified with primers possessing KpnI recognition sequences
encoded by 5~ overhangs. The URA3 fragment was then KpnI digested and ligated into
the unique KpnI site occurring within the adenovirus E 1 region sequences in the acceptor
molecule. The resulting plasmid was termed YRpETE. The construction strategy of this
molecule is detailed in Figure 3.15.
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Figure 3.15: YRpETE construction strategy. The URA3 gene ofpYES2 (BD
Biosciences Clonetech) was PCR amplified with primers possessing KpnI recognition
sequences encoded in 5' overhangs. The PCR fragment was then KpnI digested and
ligated into the unique KpnI site within the E1 region of the left-end Ad sequences in the
acceptor molecule.
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.The URA3 gene encodes the orotidine-5'-phosphate decarboxylase, which is an
essential enzYine~fri'~tlie uracil syllthesis biochemical pathway. -The URA3 gene product
converts the pyrimidine analog 5-fluoro-orotic acid (5-FOA) into a toxic product. Cells
possessing an active URA3 gene, either chromosomally or episomally, are unable to grow
on media supplemented with this chemical. Thus URA3 selection in S. cerevisiae can be
either a positive or negative selection system (Boeke et al., 1984).
3.15 URA3 peR Fragment Verification
Following PCR amplification of the URA3 selectable marker, ethanol
precipitation, and resuspension in TE buffer, the size and concentration of the amplified
product was determined by agarose gel electrophoresis (Figure 3.16). The URA3
fragment was approximately 1.1 kb (expected size 1,123 bp).
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Primers Sequence
(KpnI restriction sites underlined)
URA3F 5'-GGG GGTACCGCTTTCAATTCAATTCATC-3'
URA3R 5'-000 GGTACCGOGTAATAACTGATATAATTA-3'
Primers URA3F and URA3R correspond to positions 3840 - 3821 and
2734 - 2754 of the vector pYES2, respectively, and include 9 base
overhangs containing KpnI sites (underlined).
Figure 3.16: A) 1% agarose gel showing ethanol-precipitated resuspensions of the URA3
PCR fragment amplified from samples lacking (C) or containing pYES2 (URA3).
Marker lane is labeled M. B) Primer sequences utilized to amplify the URA3 gene from
pYES2.
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3.16 Restriction Enzyme Confmnation of YRpETE
Transformation of competent E. coli DH5a with overnight ligation reactions of
KpnI digested PCR-generated URA3 fragment from pYES2 and shrimp alkaline
phosphate treated KpnI digested YRpXC38 generated ampicillin-resistant bacterial
colonies. NdeI screening ofpDNA isolated from forty-six such ampicillin-resistant
bacterial colonies revealed that only two contained YRpXC38 clones harboring the 1,111
bp URA3 fragment (as illustrated in lane 7 ofFigure 3.17). In order to determine the
orientation of the URA3 insert within the new constructs, restriction fragment banding
pattern analysis was performed (Figure 3.17). Relative positions of the restriction sites
used to analyze YRpETE can be seen in Figure 3.15.
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Figure 3.17: 1% agarose gel showing restriction fragment banding patterns of the
parental plasmid YRpXC38 (C), and the YRpETE construct (E) digested with restriction
endonucleases AjlII, EcoRI, KpnI, or NheVHpaI. Marker lane is labeled M and marker
fragment sizes are indicated (in Kb).
The presence ofa 1.1 Kb insert was verified by comparison ofYRpXC38 and
YRpETE KpnI digests (Figure 3.17, lanes 6 and 7, respectively). Comparison of the
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AjlII and EcoRI fragments ofYRpXC38 (lanes 2 and 4, respectively) and YRpETE (lanes
3 and 5, resp~cti~eiy) revealed that the insert was not duplicated. Tlie orientation ofthe
URA3 fragment was determined by NdeVHpaI digest. The 0.6 Kb fragment generated by
this double digest confirms that the URA3 fragment was inserted in the orientation that
minimizes the distance between the unique HpaI (1637) site ofYRpXC38 and the NdeI
site occurring at position 140 ofthe URA3 PCR fragment. The exact location of the
second NdeI site in YRpXC38 is not known. It is located within the bacterial origin of
replication or the ampicillin-resistance gene. Both recombinants isolated possessed the
same restriction fragment banding patterns. The first isolate examined was termed
YRpETE and was used for all subsequent experimentation.
3.1 7 Analysis of URA3 Selectable Marker Functionality
YRpETE isolated from ampicillin-resistant E. coli DH5a was banded by CsCI
density gradient centrifugation and utilized to transform S. cerevisiae strain !y128 by
electroporation. Electroporation experiments generated an average of7.1 x 103 trp+/ura+
transfonnants/J..lg pDNA when plated on trp-/ura- SC medium, verifying the functionality
of the URA3 gene in YRpETE. YRpETE electroporation experiments plated on trp- SC
plates fortified with 5-FOA generated no colonies, further verifying the functionality of
the URA3 gene.
Transformation ofcompetent E. coli DH5(lwith total plate isolations oftrp+/ura+
s. cerevisiae transfonnant plasmid DNA generated ampicillin-resistant E. coli colonies.
Restriction endonuclease digestion ofplasmid DNA isolated from the ampicillin-resistant
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E. coli transformants yielded identical banding patterns to that of digested YRpETE
(Figure 3.18).
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Figure 3.18: A) Illustration ofNcoI sites within YRpETE. B) 1% agarose gel showing
EcoRI and NeoI restriction fragment banding patterns ofYRpETE (C) and pDNA
isolated from ampicillin-resistant bacterial colonies (A and B) generated via total plate
back transformation from trp+/ura+ yeast transformants. Marker lane is labeled M and
marker fragment sizes are indicated (in Kb).
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The ampicillin-resistant E. coli generated using isolated pDNA from the
positive yeasttrP+/~a+ transformants coupled with the identical banding patterns ofthe
digested YRpETE (the EcoRI digest is identical to that described in Section 3.16, the
digest NcoI is identical to that described in Section 3.3 except that the URA3 insert
contains one NcoI site creating 8,039bp and 806bp fragments from the 7,759bp Ncol
fragment YRpXC38) to those of all isolates examined provided sufficient proof that
positive yeast transformants indeed resulted from transformation of the yeast by
YRpETE.
3.18 Knockout In Vivo Ligation Experiments
In order to assess the utility ofthe knockout in vivo ligation system, in vivo
ligation experiments were carried out using Ajlll digested YRpETE as the acceptor. Co-
transformation ofAjlll-linearized acceptor, donor fragment, and LtIVL and RtIVL PCR
amplified linkers into S. cerevisiae and plating on trp- SC selective plates resulted in an
average of 10,200 (+/-500) trp+ colonies, approximately 1.3-fold more colonies than
control reactions lacking either donor (A+L) or linker DNA (A+D) and approximately
1.4-fold more colonies than control reactions lacking both donor and linker DNA (A)
(Figure 3.19).
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Figure 3.19: Mean and standard deviation summary of in vivo ligation reactions using
AjlII digested YRpETE acceptor. L, D, and A represent 1J.lg ofeach linker (LtIVL and
RtILV), 1Jlg of1,697 bpAjlII/AjlIII pEGFP-N1 donor fragment, and O.lJlgAjlII digested
YRpETE acceptor, respectively. Control reactions were carried out simultaneously by
omitting the donor (A+L), the linkers (A+D), or both (A).
Control reactions (A+L, A+D, A) did not differ significantly from one another by
t-test analysis. However, a significant difference between control (A+L, A+D) and in
vivo ligation (A+L+D) reactions was observed (P=0.05).
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Duplicate experiments were carried out and plated on trp- SC selective plates
supplemented with 5-FOA. An average of200 +/- 11 trp+ transformants were observed
per in vivo ligation reaction, while no transformants were observed for any control
reactions.
3.19 Knockout In Vivo Ligation Recombinant Analysis
Forty trp+ yeast transformants generated by the knockout in vivo ligation
experiments were transferred to trp-/ura- SC medium plates. Ofthese forty replica
plated isolates, only one was incapable of growth on the trp-/ura- SC medium plates,
implying that it had lost the URA3 marker and had undergone a successful in vivo
homologous recombination reaction. Plasmid DNA was isolated from this transformant
and from thirty transformants growing on trp- SC medium supplemented with 5-FOA.
Similarly, resistance to 5-FOA implied that these yeast transformants had lost a
functioning URA3 marker and had undergone a successful in vivo homologous
recombination reaction. This DNA was utilized to back-transform competent E. coli.
Plasmid DNA isolated from ampicillin-resistant colonies generated by each back-
transformation was subsequently analyzed by EcoRI digestion (Figure 3.20).
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Figure 3.20: 1% agarose gel showing EcoRl digested plasmid DNA ofYRpXC-EGFP
control (C), knockout in vivo ligation generated recombinant plasmid isolated by replica
plating from trp- SC medium to trp-/ura- SC medium (RP), and knockout in vivo ligation
generated recombinant plasmids isolated using trp and 5-FOA selection (1-8). M
indicates marker lane and marker fragments sizes are given (in Kb).
Whether isolated by replica plating from trp- SC medium to trp-/ura- SC
medium or by selection on trp- SC medium supplemented with 5-FOA selection, all yeast
transformants that possessed a ura- phenotype had undergone a successful in vivo
homologous recombination reaction and showed identical EcoRI banding patterns to that
ofYRpXC-GFP generated by in vivo ligation reactions using Af]]! digested YRpXC38 as
substrate. Since earlier recombinant plasmid sequencing and GFP expression analysis
had demonstrated the fidelity of in vivo plasmid construction, no further characterization
of recombinant plasmids was performed.
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3:20 Knockout In Vivo Ligation Reactions Using a Partially Digested
Acceptor
Given the previously observed low frequency of recombinant plasmid
generation (4 %) when using a unique cohesive-end generating restriction enzyme to
linearize the acceptor, it would be expected that using a partially digested acceptor with
three cohesive-end recognition sites would generate far too much background to be
considered a feasible option. However when manipulating the large plasmids associated
with adenovirus research, very often the use ofnon-unique restriction sites may be the
only option in manipulating a particular region of the genome. Knockout in vivo ligation
has been shown to be an extremely effective screening tool, and as such may be able to
overcome the limitations ofworking with non-unique restriction sites.
In order to further examine the utility of the knockout in vivo ligation system,
knockout in vivo ligation reactions utilizing a partial Sac!! digestion of the YRpETE
acceptor were carried out. Figure 3.4 depicts these sites in YRpXC38 at positions 414,
3708, and 5708. Insertion of the URA3 marker changes the positions of these sites to
414, 5004, and 6658, relative to EcoRI(1) in YRpETE. Since SacII sites occur on both
sides ofthe URA3 gene in YRpETE, purified single cut acceptor was utilized to prevent
false positives that might be generated by recombinants and ligation products deleting the
URA3 selectable marker (Figure 3.21).
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Figure 3.21: A) 1% agarose gel showing partial digestion series ofYRpETE with
SacII. Lanes 1 through 9 contain digests incubated for increasing 15 second intervals.
Arrow indicates single cut fragment. B) Illustration ofSacII restriction site locations
in YRpETE.
Single cut SacII digested YRpETE was isolated and used as acceptor in
knockout in vivo ligation reactions, and the results summarized in Figure 3.22.
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Figure 3.22: Mean and standard deviation summary ofmockout in vivo ligation
reactions using single cut SacII digested YRpETE acceptor. L, D, and A represent If.lg
of each linker (LtIVL and RtILV), If.lg of1,697 bpAjlII/AjlIII pEGFP-NI donor
fragment, and 0.1 J.lg single cut SacII digested YRpETE acceptor, respectively. Control
reactions were carried out simultaneously by omitting the donor (A+L), the linkers
(A+D), or both (A).
Control reactions lacking donor (A+L) or linker DNA (A+D) or both (A) did
not differ significantly from one another or from knockout in vivo ligation reactions
single cut SacII digested YRpETE acceptor (A+L+D) by t-test analysis. Because no
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significant difference was observed between experimental and control reactions replica
plating analysis from trp- SC plates onto trp-/ura- SC media piates was not performed.
Negative selection using trp- SC 5-FOA supplemented fortified plates yielded an average
of 50 +/- 9 trp+ 5-FOA resistant yeast colonies per in vivo ligation reaction, while no
colonies were observed as a result of control reactions. Plasmid DNA was isolated from
twenty trp+ 5-FOA resistant transformants and back-transformed into competent E. coli.
Plasmid DNA from 20 ampicillin-resistant E. coli colonies produced EcoRI restriction
fragment banding patterns identical to those observed in Figure 3.19.
In order to compare screening workloads accompanying knockout and
traditional in vivo ligation, identical in vivo ligation reactions were carried out using
single cut SacII partially digested YRpXC38 acceptor (Figure 3.23).
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Figure 3.23: Mean and standard deviation summary ofknockout in vivo ligation
reactions using single cut SacII digested YRpXC38 acceptor. L, D, and A represent 1J.lg
of each linker (LtIVL and RtILV), If..lg of 1,697 bp AjlII/AjlIII pEGFP-Nl donor
fragment, and O.lf..lg single cut SacII digested YRpXC38 acceptor, respectively. Control
reactions were carried out simultaneously by omitting the donor (A+L), the linkers
(A+D), or both (A).
Plasmid DNA was isolated from trp+ yeast transformants generated during in
vivo ligation reactions using single cut SacII partially digested YRpXC38 acceptor.
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Restriction enzyme screening ofplasmid DNA from one hundred ampicillin-resistant E.
coli produced by'back~transforrriationwith the isolated plasnlld DNA yielded only ~
YRpXC38 parental plasmid and no recombinant plasmid.
Reaction efficiencies (trp+ yeast transformants) for knockout in vivo ligation
reactions using partially digested single cut acceptor were two-fold lower than those
obtained utilizing the AjlII digested acceptor. The decrease in efficiency was most likely
due to the three populations ofacceptor utilized in the single cut SacII digested acceptor
in vivo ligation reactions which would have decreased the abundance ofacceptor suitable
for homologous recombination. In addition, the method chosen to purify the acceptor
from agarose gels could have sheared a small percentage of the acceptor molecules or
rendered the DNA incapable ofundergoing recombination in some other fashion.
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4. Discussion
4.1 Results Relevant to General In Vivo Ligation Research
Given the ability of in vivo ligation to foster both deletions and insertions, the
term recombinational cloning will be used interchangeably with the term in vivo ligation
throughout the remainder of this thesis.
The main purpose ofthis study was to develop and evaluate protocols that would
facilitate the large plasmid manipulations common to adenovirus manipulation by
recombinational cloning. Successful secondary in vivo ligation experiments revealed
high numbers ofbackground yeast transfonnants (3/70 recombinant plasmids) that
imposed a lengthy screening process in order to isolate the desired recombinant plasmid.
Presumably the high frequency of acceptor plasmid regeneration reflects a tendency ofS.
cerevisiae to preferentially repair ds DNA breaks with cohesive ends before attempting
plasmid repair through homologous recombination. Klenow treatment of linearized
acceptor was found to drastically reduce the regeneration of the acceptor plasmid and
decrease screening workload (3/70 recombinants as compared to 9111 for untreated and
Klenow treated acceptor, respectively). When unique restriction sites for acceptor
linearization were not available, knockout recombinational cloning was shown to provide
zero background screening (0/100 recombinant plasmids generated by recombinational
cloning isolated from back transformed E. coli as compared to 20/20 using knockout
recombinational cloning when partially digested acceptor was used in both cases). No
recombinants other than those containing the predicted conformation were observed
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during knockout recombinational cloning, however only a proportion of the total number
ofrecombin;nts~wereanalyzedfor each reaction and some other recombiriants may have
been generated and simply not observed.
In vivo ligation is still a relatively novel technique, and as a result the mechanisms
underlying its success are not fully understood. Analysis of the failed in vivo ligation
attempts and subsequent success bring the processes involved during in vivo ligation
closer to being fully understood.
Initial in vivo ligation attempts utilizing HpaI restricted acceptor (Figure 3.4) and
in vivo ligation trials utilizing AjlII digested Klenow-treated acceptor (Figure 3.4)
generated recombinants ofunexpected structure. Recombinants generated were of two
distinct populations during initial in vivo ligation trials (bearing a small 1.1 kb deletion
flanked by SacII (414) and KpnI (2115), or bearing a larger 2.6-2.7 kb deletion flanked
by SacII (414) andAjlII (3596)), and only one recombinant was observ~d in trials
utilizing AjlII-digested Klenow-treated acceptor.
Recombinants generated during initial in vivo ligation trials can be explained by
examining regions ofmicrohomology within the Ad5 left-end sequences. The E1A and
EIB promoters drive early gene function, and the sequence homology reflecting that
similarity in function is evident when those promoter sequences are examined (Figure
4.1).
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E1A (431-498) gcgttttattattatagtcagctgacgtgtagtg tatttata cccggtgagttcctcaagaggccac
E1B (1641-1701) tggcgtgttaaatggggcggggcttaaaggg tatataa tgcgccgtgggctaatcttggttaca
IX (3520-3584) tgtgtgggcgtggcttaagggtgggaaagaa tatataa ggtgggggtcttatgtagttttgtatc
Figure 4.1: Promoters occurring in the left-end of the Ad5 genome. AflII site indicated
by bold type. Nucleotide positions are listed as defined by Genbank Accession X02996.
Homology between these promoter regions is not precise, but it is plainly
observable even without performing sequence alignment. The TATA boxes are
surrounded on either side by stretches of G/T rich runs ofmore than 20 bp (Figure 4.1).
Mezard et ale (1994) demonstrated that minimal sequence homology of2-21 bases is
necessary for illegitimate recombination. Yeast recombination machinery is very
efficient, and will not tolerate broken DNA (Mezard et al., 1994; Mezard and Nicolas,
1994; reviewed in Sung et al., 1999). In the absence ofhomology with which to correct
ds DNA breaks, illegitimate recombination is used to correct the damaged DNA (Mezard
and Nicolas, 1994). The generation of two distinct populations ofdeletion recombinants
resulting from intramolecular illegitimate recombination within the acceptor during initial
in vivo ligation experiments is likely due to the probability that the recombination
machinery would most likely repair the gap with regions ofmicfohomology that are
proximal rather than distal to the ds DNA break. The smaller deletion is likely generated
by recombination between the E1A and EIB promoter regions. This recombination event
may have been favored (and t~us more prevalent in 38 out of40 recombinant plasmids
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analyzed) because the E1Bpromoter region more closely flanks the ds DNA break site
(HpaI (1637) slte)'thall do the protein IX promoter regions involved-in creating the less
prevalent larger deletion product (Figures 3.4 and 4.1). The E1A promoter would be
predicted to be involved in any such intramolecular illegitimate recombination reaction
since it is the only region ofmicrohomology to the EIB or protein IX promoters on its
side of the ds DNA break (Figures 3.4 and 4.1). These results echo previous results
obtained by Mezard and Nicholas (1994) in the efficiency of recombinant generation by
illegitimate recombination (Liel transformation was used with comparable efficiency to
that observed for electroporation in this report, perhaps owing to the much larger size of
plasmids utilized herein), and in the generations ofdistinct populations ofrecombinants
generated by intramolecular recombination in the absence-of sufficient homology
between broken ends ofDNA fragments at the site of the ds DNA break.
The rare occurrence of the recombinant generated during Klenow-assisted in vivo
ligation trials could be explained by assuming that a minute population ofcells existed in
each reaction that took up acceptor, but failed to take up linker and/or donor DNA. In
such a case illegitimate recombination would be the only option by which to repair the
acceptor. Additionally, since no regeneration of the acceptor was observed during these
in vivo ligation reactions, the forty-minute Klenow treatment was sufficient to diminish
the presence ofcohesive-end acceptor to undetectable levels.
Only after the ds DNA break was repositioned so that the regions of linker
generated homology overlapped with the site of the ds DNA break (AjlII site at position
3596, and SacII at position 414, Figure 3.4), was successful homologous recombination
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observed and the desired recombinant obtained. The success of these reactions is most
easily explailledby-C-examining the current model of the ds-ONA break repair pathway of
S. cerevisiae (Figure 3.8). This model dictates that homology to be utilized for repair
must occur at (or near) the site of the ds DNA break (Sung et al., 1999). When viewed
in the context of the above mentioned pathway, the failure of initial in vivo ligation
experiments to produce the desired recombinant may have been due to the lack of
available homology within the acceptor near the site of the ds DNA break. The ss DNA
tails generated during ds DNA break repair have been documented to be up to lkb in
length (Figure 3.8; reviewed in Sung et al., 1999). However the distance between the ds
DNA break and the regions ofhomology supplied by the linkers during initial in vivo
ligation experiments was greater than 1.2 kb in either direction. Two fragment in vivo
ligation reactions have in fact been successfully attempted with distances of340 bp and
580 bp separating the regions ofPCR generated homology from the ds DNA break
(Oldenburg et al., 1997). It is likely that distances separating the regions of linker
generated homology during initial in vivo ligation reactions were simply too great for the
yeast recombination machinery to overcome.
Once conditions conducive to successful in vivo ligation were provided,
recombinants ofthe predicted conformation were observed much more frequently than
were other recombinants. It is likely that once initial recombination events had occurred
and incorporated the regions of linker homology, sufficient homology was present to
complete the in vivo ligation reaction. This deduction is consistent with previous
observations that repair is shunted into illegitimate recombination pathways only when
homologous recombination fails (Mezard et aI., 1994; reviewed in Sung et al., 1999).
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Once conditions for successful in vivo ligation were provided the desired
recombinant-plasmId-was obserVed in only 4 % (3/70) of-ampicillin resistant bacterial
colonies analyzed during in vivo ligation reactions using AjlII digested YRpXC38. If the
assumption is made that the numbers ofbacterial transformants harboring the
recombinant plasmid of interest are proportional the to numbers ofyeast transformants
harboring the same plasmid, expanding this percentage using the average total number of
trp+ yeast transformants generated during these in vivo ligation reactions (11000 positive
transformants, from Figure 3.9) yields an expected number of471 recombinants ofthe
desired conformation. An average of only 200 -recombinants was achieved during
knockout in vivo ligation reactions plated on trp-/5-FOA supplemented SC medium when
the same restriction site (Af]]l) was utilized to linearize the acceptor. Since no yeast
colonies growing on trp-/S-FOA supplemented SC medium were observed to harbor
plasmid other than the desired recombinant, it will be assumed that all 200 of this average
carry the plasmid of interest (though this could only be determined by direct examination
of all yeast colonies' pDNA). Despite the 1.1 kb increase in size of the YRpETE
acceptor, no significant difference in transformation efficiency was observed between the
in vivo ligation and knockout in vivo ligation experiments (by Student's t-test). Since no
detectable difference in transformation efficiency was detected, a comparison of these
,two values (471 and 200 yeast transformants carrying the desired plasmid recombinant)
indicates a decrease in efficiency as the size of the deletion increased. However since the
total numbers yeast colonies harboring the desired recombinant plasmid generated must
be implied from measured data and were not directly measured, no definitive statements
about the effect of increasing deletion size can be made from this report
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The restriction sites necessary for incorporation of both the yeast selectable
markers andARs- -sequences were present in positions convement fOf the -construction of
plasmids described herein. This may not be the case for other cloning vector systems.
The TRP1/ARS and URA3 fragments mentioned in this report are sufficiently short that
they can be amplified by peR and subsequently utilized for two fragment
recombinational cloning reactions (Figure 4.2). Furthermore, if such a strategy were to
be undertaken, integration events and peR and recombination-induced mutations
disrupting the proper function ofthese markers or replication sequences would be
effectively filtered out by the selective pressure ofplating on the appropriate yeast
selective medium and recovery of the recombinant plasmid by total plate back-
transformation into E. coli.
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Figure 4.2: General strategy for the creation of recombinational cloning vectors by two-
fragment recombinational cloning.
In hindsight, a similar strategy could have been implemented to insert the
TRPllARS fragment into pXC38, and the URA3 fragments into the YRpXC38 plasmid.
In fact, I have successfully attempted such a strategy during the production ofgeneral-
purpose knockout recombinational cloning vectors (unpublished data).
Given the advantages of recombinational cloning over traditional in vitro DNA
manipulation techniques it may be only a matter or time before all cloning vectors
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possess the necessary yeast replication and selectable marker sequences to facilitate both
a.-- -:.~ _. _ ....... _ _ _ ~
traditional and recombinational cloning.
4.2 Future Ad Research Involving Recombinational Cloning.
Because the adenovirus system presents a unique set of challenges in successfully
manipulating the genome, other facets of Ad research presenting similar challenges to
rescue vector manipulation could benefit from the use of in vivo ligation strategies.
One of the major hurdles ofAd mediated gene therapy has been a mounted
immune response against both the vector itself and the transgene product (Yang et al.,
1994; Dai et al., 1995; van Ginkel et aI., 1997). The discovery of an immune response
directed against first-generation Ad vectors has spawned the development of increasingly
crippled vectors: second-generation vectors with additional deletions in £2, E3, and £4
regions, and third-generation "gutless" Ad vectors lacking all viral genes. Unfortunately,
these vectors continue to suffer from various weaknesses such as residual low-level viral
gene transcription and low-level replication competent adenovirus contamination,
respectively (reviewed in Benihoud et al., 1999). Research into novel second generation
Ad vectors is particularly hampered by the current time investment involved in creating
novel recombinants, since the trade-offbetween cost and benefit ofeach combination of
viral genes must be analyzed and helper-cell lines expressing viral genes deleted from
matched viral genomic vector systems must be developed for each combination. The use
of in vivo ligation to generate large site-specific deletions would vastly simplify matched
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genomic vector construction strategies by enabling the researcher to extend adenovirus
genome deletions to exact nucleotide positions, thus preventing homologous
recombination between helper-cell encoded viral genes and the viral genome (Figure
4.3).
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Figure 4.3: Construction strategy for generating matched genomic vectors for novel
helper-cell lines. Virus genomic deletions must extend beyond the boundaries ofvirus
sequences integrated into the cell-line genome to prevent homologous recombination and
rescue of the deleted virus sequences into the viral genome.
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Likewise, modification and control of Ad vector tropism by genetic engineering
of the capsid (Dffiitriev et al., 2002; recently reviewed iri"NIcklin and-Baker, 2002 and
Barnett et aI., 2002) is limited only by the speed at which novel recombinants can be
generated. These targeted Ad vectors have shown great promise for not only gene
therapy, but for controlling immune responses involved in transplantation rejection
(Bilbao et al., 2002) and for cancer therapy (Suzuki et al., 2001).
If only small insertions must be made to an acceptor, as may be the case when
adding short nucleotide sequences encoding targeting peptides to coding regions for
capsid proteins, the site-specific mutagenesis strategy offered by Kitagawa and Abdulle
(2002) would be the ideal alternative to a tedious in vitro insertion strategy. Overlapping
regions ofhomology encoding insert sequences created entirely by PCR would allow
targeted, in-frame insertions at virtually any position within the genome where a
restriction site is available to linearize the acceptor (Figure 4.4).
The advantage of this system over traditional linker insertion strategies lies in the
fact that oligonucleotides can only be generated up to a maximum length of 110 bases
(www.genosys.com).This grossly limits such strategies due to lack of convenient
restriction sites proximal to the region to be altered. PCR/recombination-based strategies
would allow the use ofmore convenient, but distal restriction sites,· because peR can
easily generate products of greater than lkb for recombinational cloning.
Such strategies may require the addition ofa proof-reading enzyme. In this study
a sequence error was detected in one of the three in vivo ligation generated recombinants
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within a region of linker generated homology and similar errors would be more abundant
in sequences derived from overlapping linker regions.
PCR
amplification
Homologous
Recombination
in S. cerevisiae
Figure 4.4: Insertion/deletion recombinational cloning strategy utilizing PCR generated
insert donor DNA (white block).
As a consequence oftropism modified Ad vectors becoming able to infect a
growing number ofcell types, the need for the transgene expression to be tightly
regulated will be of the highest priority. Immune response directed against transgene
products in unintended cell types, in particular professional antigen presenting cells, can
be abrogated through the use of tissue-specific promoters (Weeratna et al., 2001). Such
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tissue-specific (Larochelle et al., 2002; Ribault et a/., 2001) and tumor-specific (Qiao et
al., 2002) promote-rs-have been used successfully in this capacity.
With the discovery ofnovel tissue-specific (Asnagli et a/., 2002; Wolfe et al.,
2002) and tumor-specific (Cao et al., 1998) promoters, the development ofnovel second
and third generation Ad vectors, and novel tropism modification strategies becoming
available, improved construction strategies for generating Ad vectors will be required. In
vivo ligation and knockout in vivo ligation have been shown to be extremely effective Ad
genome manipulation tools.
Yeast artificial chromosome (YAC) (Ketner et a/., 1994) and E. coli plasmid-
based recombinational cloning systems (Chartier et al., 1996; Crouzet et al., 1997; He et
a/., 1998; Souza and Armentano, 1999; Youil et al., 2001) for the creation ofAd vectors
offer the ability to manipulate the entire viral genome by relying on the high rates of
homologous recombination in E. coli and S. cerevisiae. Recombinant full-length viral
genomes are generated by recombination between small targeting vectors containing
homology to the region of the viral genome to be altered and large bacterial plasmids or
YACs containing the viral genome. In addition, these recombinant vectors can then be
restriction enzyme digested releasing full-length recombinant viral genomes. Virus rescue
efficiency by transfection ofpermissive cell-lines with these full-length recombinant
genomes is far more efficient than virus rescue by plasmid co-transfection and
subsequent in vivo recombination (Ketner et al., 1994; Chartier et al., 1996; Crouzet et
al., 1997; Kojima et al., 1998). While these methods improve virus rescue efficiency,
they have yet to become widely utilized. The production ofthe recombinational targeting
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vectors used to alter the viral genome is hampered by restriction enzyme recognition site
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availability. Consequently, these methods currently offer no improvement over traditional
in vitro manipulation of the viral genome.
Using in vivo ligation and/or knockout in vivo ligation to generate plasmids for
recombinationally targeted cloning for use with these above mentioned systems would
allow unprecedented ease ofAd genome manipulation in regions of the genome with
previously poor accessibility due to a lack of available, unique restriction sites. This
report demonstrates that insertions and deletions can be made using in vivo ligation
strategies described herein without the need for unique or multiple restriction sites. Such
a system would offer the potential to produce many novel recombinant Ad vectors with
minirilal construction time.
The final hurdle to overcome in Ad-mediated gene delivery is the abrogation of
the immune response to Ad gene therapy vectors and their transgene products. Progress
in this field is limited only by the ability to successfully generate novel recombinants.
The in vivo ligation systems described herein may offer the potential to bring Ad-
mediated gene replacement therapy, cancer therapy, and vaccination out of the realm of
science fiction and into the realm of routine medical procedure.
4.3 Future Research Questions
This report has demonstrated the importance ofthe position of the ds DNA break
relative to the position of linker-supplied homology during in vivo ligation mediated
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insertion and deletion reactions. However, new questions have been.generated by this
discovery. to ~liai eXtent does the size of the deletion t·obe- made depend on the amount
of the linker-provided homology? Also, to what extent (ifany) can the position of the ds
DNA break within the acceptor extend beyond the regions of linker-supplied homology?
In Section 3.8 it was demonstrated that a 1,197 bp region separating the DS DNA break
and the leftward site of linker-supplied homology inhibited successful in vivo ligation.
As previously mentioned, two fragment in vivo ligation reactions have been successfully
attempted with distances of 340 bp and 580 bp separating the regions ofPCR generated
homology from the ds DNA break (Oldenburg et al., 1997). As mentioned herein, it is
likely that a limiting factor defining acceptable distances from the PCR-generated
homology to the site of acceptor linearization is the size of the ss DNA tails produced
during ds DNA break end processing. These two reports could be used as a starting point
to define the upper limits of distances separating ds DNA break from PCR generated
homology which still produce successful recombinational cloning.
Finally, it has always been assumed that in vivo ligation operates through the ds
DNA break/repair pathway (Raymond et al., 1999). However, data presented herein
suggest that it is likely that episomal DNA replication and subsequent repair is the
mechanism underlying successful in vivo ligation.
Current hypotheses regarding replication fork faltering and repair in yeast rely
heavily on the concept that replication forks can collapse, while homologous
recombination can be utilized by the cell to repair these faltering replication forks
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(Kuziminov, 2001, and references therein). Repair of ds DNA breaks by homologous
recombination is'believed to be initiated by faltering DNA replication events as follows:
i) As a replication fork encounters an unrepaired DNA lesion in the template
DNA, it collapses, generating a ds end. (Figure 4.5, A to B to C).
ii) Repair enzymes are recruited and the double-strand end is processed to
produce a 3' ssDNA overhang, which is subsequently complexed with ssDNA
binding proteins (Figure 4.5, C)
iii) This complex mediates invasion or the ssDNA end into homologous DNA
sequences to be used as repair substrate, and forms a recombination
intermediate resembling a replication fork (Figure 4.5, D).
iv) Subsequent resolution of the Holliday junction behind the reassembled fork
structure (Figure 4.5, D to A) restores template DNA integrity allowing
replication to continue by "excising" template DNA containing the break.
128
(A)
(B)
(C)
::::::::::::::::::::::::::::...e
~
..::::.:::::u.::·:u::::: e
~
129
Figure 4.5: Pathway ofreplication fork stalling/collapse with subsequent resetting/repair.
DNA duplexes are shown as double lines. (A) A replication fork. (B) The replicatio.n
fork approaching a ds DNA break. (C) The replication fork collapses at the interruption
and the ds end and is enzymaticly degraded to produce a 3' overhang. (D) Invasion of
homologous DNA and resolution of the Holliday junction to restore replication fork
structure. Newly replicated DNA is indicated by hatched lines.
According to this view of coupled DNA replication and repair, recombination
induced by a block in replication generated by a ds break would only proceed if sufficient
homology at or near the site ofthe ds DNA break were present. One can envision the in
vivo ligation reactions performed in this report as a series of replication fork falterings
and reassembly. The ds DNA break would lead to replication fork recession and strand
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invasion within the regions of homology provided by the appropriate linker and
subsequent ~parr -by-homologous recombination. This proces-s would repeat
itself incorporating the donor fragment and the second linker region into the growing
DNA duplex. The only way to regenerate the circular topology of the plasmid would
then be for the final linker mediated homologous recombination to occur.
The most compelling evidence that DNA repair necessary for recombinational
cloning initiation by replication rather than by the ds break repair pathway comes from
the observation that initial in vivo ligation reactions produced no detectable recombinant
plasmid. Donor and linker fragments were available as substrate for the ds DNA break
repair pathway at much higher concentrations than the acceptor during initial in vivo
ligation reactions, and yet these reactions failed to produce the desired recombinant
plasmid. It was only after repositioning of the ds DNA break during secondary in vivo
ligation reactions that successful recombinational cloning was detected. Furthermore, it
has been demonstrated that intact donor plasmid can be used as substrate for
recombinational cloning (Gunyuzlu et aI., 2001). These data demonstrate that the
position ofacceptor linearization is a key to successful recombinational cloning and
provides some basis for the argument that recombinational cloning is indeed initiated by .
acceptor fragment replication rather than by the ds DNA break repair pathway, as was
originally assumed (Oldenburg et al., 1997; Raym~nd et al., 1999). Undoubtedly, both
pathways ultimately contribute to the final outcome. The question of which system, ds
DNA breakage repair or DNA replication leading to subsequent DNA repair initiates in
vivo ligation should be definitively addressed.
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5. Conclusions
The primary goal of this research was to analyze the ability of in vivo ligation to
manipulate the adenovirus system in an attempt to circumvent many of the problems
associated with in vitro manipulation by traditional cloning techniques. By mimicking a
deletion that involved a cumbersome multi-step construction strategy, we have
demonstrated that in vivo ligation can hasten production of rescue vectors by creating
precise insertions and deletions in a single step without the need for multiple or unique
restriction enzyme recognition sites.
Traditionally, recombinational cloning systems have utilized YEp or YCp yeast
plasmid systems. Insertion of these large sequences in addition to the necessary yeast
selectable markers into traditional cloning vectors involves time-consuming multi-step
cloning procedures. The discovery that the 1,456 bp TRP1/ARS fragment of YRp7,
which is small enough to be readily amplified by PCR, is sufficient for efficient in vivo
ligation may open up the advantages of recombinational cloning to systems that have
previously not examined the possibility ofutilizing recombinational cloning.
It has been generally assumed that the amount ofPCR-generated homology was
the most important aspect ofany in vivo ligation reaction (Oldenburg et a!., 1997; Hua et
a!., 1997). Herein we demonstrated that not only the amount and location ofPCR-
generated homology, but the location ofthe ds break relative to that homology, and the
size ofdeletions being carried out should be viewed as essential elements to be
considered in each in vivo ligation reaction.
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Modification of existing recombinational cloning protocols as described herein
• - - - - -to ..
facilitates the use of recombinational cloning strategies that are otherwise impractical for
use with larger plasmid systems. Klenow fill-in reactions of cohesive ends in digested
acceptor DNA and yeast selectable marker deletion have been determined to vastly
decrease screening workload for recombinant plasmids. The zero background screening
system utilizing URA3 gene deletion coupled with simultaneous 5-FOA positive selection
and negative selection has been termed 'knockout' in vivo ligation.
The ability of in vivo ligation to produce site-specific recombination without the
need for unique or multiple restriction enzyme recognition sites represents a substantial
improvement over current cloning techniques. The ability ofknockout recombinational
cloning to generate precise insertions and deletions in a short time while providing zero
background screening could be essential in the development of systems requiring precise
DNA manipulation.
132
133
References
Anderson, R.D., Haskell, R.E., Xia, H., Roessler, B.l., and Davidson, B.L. 2000. A simple
method for the rapid generation of recombinant adenovirus vectors. ·Gene Therapy. 7:
1034-1038.
Aoki, K., Baker, C., Danthinne, X., Imperiale, M.J., and Nabel, G.J. 1999. Efficient generation
of recombinant adenoviral vectors by Cre-Iox recombination in vitro. Mol. Med. 5: 224-
231.
Asnagli, H., Afkarian, M., and Murphy, K.M. 2002. Identification ofan Alternative GATA-3
Promoter Directing Tissue-Specific Gene Expression in Mouse and Human. J Immunol.
168(9): 4268-4271.
Babiss, L.E., Ginsberg, H.S., and Darnell, J.E. Jr. 1984. Adenovirus EIB proteins are required
for accumulation of late viral mRNA and for effects on cellular mRNA translation and
transport. Mol. Cell. Bio!. 5: 2552-2558.
Ballay, A., Levrero, M., Buendia, M., Tiollais, P., and Perricaudet, M. 1985. In vitro and in vivo
synthesis ofthe hepatitis B surface antigen and of the receptor for polymerized human
serum albumin from recombinant human adenoviruses. EMBO J 4(13B): 3861-3865.
Barnett, B.G., Crews, C.J., and Douglas, J.T. 2002. Targeted adenoviral vectors. Biochim.
Biophys. Acta. 1575(1-3): 1-14.
Bautista, DS, Hitt, M., McGrory, J., and Graham, F.L. (1991). Isolation and characterization of
insertion mutants in E1A of adenovirus type 5. Virology. 182(2): 578-96.
Becker, D.M., and Guarente, L. 1991. High efficiency transformation ofyeast by
electroporation. Methods Enzymol. 194: 182-187.
134
Benihoud, ., Ye~P.,~·and-Perricaudet, M. 1999. Adenovirus'-ve-ctors for-gene-delivery: Curro
Opine Biotechnol. 10: 440-447.
Bergelson, J.M., Cunningham, J.A., and Droguett, G. 1997. Isolation ofa common receptor for
Coxsackie B viruses and adenoviruses 2 and 5. Science. 275: 1320-1323.
Bett, A.J., Haddara, W., Provoke, L., and Graham, F.L. 1994. An efficient and flexible system
for construction ofadenovirus vectors with insertions or deletions in early regions 1 and 3.
Proc. Natl. A cad. Sci. USA. 91: 8802-8806.
Bilbao, G., Contreras, J.L., Dmitriev, I., Jenkins, S., EdkhotI: D., Thomas, F., Thomas, J., and
Curiel, D.T. 2002. Genetically modified adenovirus vector containing an ROD peptide in
the ill loop of the fiber knob improves gene transfer to nonhuman primate isolated
pancreatic islets. Am. J. Transplant. 2(3): 237-243.
Boeke, J.D., LaCroute, F., and Fink, G.R. 1984. A positive selection for mutants lacking
orotidine-5'-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance.
Mol. Gen. Genet. 197: 345-346.
Broker, T.R. 1984. Animal virus RNA processing. p. 181-212. In Processing ofRNA. CRC
Press, Boca Raton.
Burget, H-G., and Kvist, S. 1987. The E3/19Kd proline ofadenovirus type 2 binds to the
domains ofhistocompatibility antigens required for CTL recognition. EMBO J. 6: 2019-
2026.
135
Cao,G.W., Qi, Z~T~,~p-an~'z., Zhang;X.Q., Miao, X.H., Feng·,-Y.-, Lu, X.H., Kuriyama,-"S., and
Du, P. 1998. Gene therapy for human colorectal carcinoma using human CEA promoter
controlled bacterial ADP-ribosylating toxin genes human CEA: PEA & DTA gene
transfer. World J Gastroenterol. 4(5): 388-391.
Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., and Mehtali, M. 1996.
Efficient generation of recombinant adenovirus vectors by homologous recombination in
Escherichia coli. J Virol. 70(7): 4805-4810.
Chen, P.H., Omelles, D.A., and Shenk, T. 1993. The adenovirus L3 23-kilodalton protein
cleaves the amino-terminal head domain from cytokeratin 18 and disrupts the cytokeratin
network ofHeLa cells. J Virol. 67: 3507-3514.
Crouzet, J., Naudin, L., Orsini, C., Vigne, E., Ferrero, L., Le Roux, A., Benoit, P., Latta, M.,
Torrent, C., Branellec, D., Denefle, P., Mayaux, J., Perricaudet, M., and Yeh, P. 1997.
Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc.
Natl. Acad Sci. USA 94: 1414-1419.
Dai, Y., Schwarz, E.M., Gu, D., Zhang, W., Sarvetnick, N., and Verma, I.M. 1995. Cellular and
humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization
of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci.
USA. 92: 1401-1405.
Davis, A.R., Meyers, K., and Wilson, J.M. 1998. High throughput method for creating and
screening recombinant adenoviruses. Gene Therapy. 5(8): 1148-1156.
136
DeMarini, D.J.,Creasy, C-.L.;Lu, Q~, Mao, J., Sheardown, S:A.,- Sathe, G.M-.: and Livi~ G.P.
2001. Oligonucleotide-Mediated, PCR-Independent Cloning by Homologous
Recombination. BioTechniques. 30: 520-523.
Dmitriev, I.P., Kashentseva, E.A., Curiel, D.T. 2002. Engineering ofadenovirus vectors
containing heterologous peptide sequences in the C terminus of capsid protein IX. J
Virol. 76(14): 6893-6899.
Everitt, E., Sudquist, B., Pettersson, D., and Philipson, L. 1973. Structural proteins of
adenoviruses. X. Isolation and topography of low molecular weight antigens from the
virion of adenovirus type 2. Virology. 62: 130-147.
Fields, B.N., Knipe, D.M., and Howley, P.M. 1996. Fundamental Virology, Third Edition.
Raven Press, Philadelphia.
Ghosh Choudhury, G., Haj Ahmad, Y., Brinkley, P., Rudy, J., and Graham, F.L. 1986. Human
adenovirus cloning vectors based on infectious bacterial plasmids. Gene. 50: 161-171.
Ghosh Choudhury, G., Haj Ahmad, Y., and Graham, F.L. 1987. Protein IX, a minor component
of the human adenovirus capsid, is essential for the packaging of full length genomes.
EMBOJ. 6: 1733-1739.
Ginsberg, H.S., Noldawer, L.L., Sehgal, P.B., Redington, M., Kilian, P.L., Chanock, R.M., and
Prince, G.A. 1991. A mouse model for investigating the molecular pathogenesis of
adenovirus pneumonia. Proc. Natl. Acad. Sci. USA. 88: 1651-1655.
Giraldi, P., Courtney, M., Pavirani, A., and Perricaudet, M. 1990. Expression ofhuman cx 1-
antitrypsin using a recombinant adenovirus vector. FEBS Lett. 267(1): 60-62.
137
Graeble, M., andHeaimg,-'P. 1990. -Adenovirus type 5 packagmg domain is -composea of a
repeated element that is functionally redundant. J. Virol. 64(3): 2047-2056.
Graham, F.L., and Provoke, L. 1995. Methods for Construction ofAdenovirus Vectors. Mol.
Biotechnol. 3: 207-220.
Graham, F.L., Smiley, J., Russell, W.C., and Narin, R. 1977. Characteristics ofa human cell line
transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36: 59-72.
Greber, V.F., Willetts, M., Webster, P., and Helenius, A. 1993. Stepwise dismantling of
adenovirus 2 during entry into cells. Cell. 75: 477-486.
Gunyuzlu, P.L., Hollis, G.F., and To~ J.H. 2001. Plasmid Construction by Linker Assisted
Homologous Recombination in Yeast. BioTechniques. 31(6): 1246-1250.
Haj-Ahmad, Y., and Graham, F.L. 1986. Development ofa helper-independent human
adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase
gene. J Virol. 57(1): 267-274.
Hardy, S., Kitamura, M., Harris-Stansil, T., and Dai, Y. 1997. Construction ofadenovirus
vectors through Cre-Iox recombination. J. Virol. 71(3): 1842-1849.
Hay, R.T., and Russell, W.C. 1989. Recognition mechanisms in the synthesis of animal virus
DNA. Biochem. J. 258: 3-16.
He, T., Zhou, S., Da Costa, L.T., Yu, J., Kinzler, K.W., and Vogelstein, B. 1998. A simplified
system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95: 2509-
2514.
138
Hehir, K.M., Armentano~D., Cardoza, L.M., Choquette, T.t~, J3erthelette, P-.B., White, G.A.,
Couture, L.A., Everton, M.B., Keegan, J., Martin, J.M., Pratt, D.A., Smith, M.P., Smith,
A.E., and Wadsworth, S.C. 1996. Molecular Characterization ofReplication-Competent
Variants ofAdenovirus Vectors and Genome Modifications ofPrevent Their Occurrence.
J Virol. 70(12): 8459-8467.
Hermens, W.T.J.M.C., and Verhaagen, J. 1997. Adenoviral Vector-Mediated Gene Expression
in the Nervous System ofImmunocompetent Winstar and T Cell-Deficient nude Rats:
Preferential Survival ofTransduced Astroglial Cells in nude Rats. Hum. Gene. The. 8:
1049-1063.
Hisanori, K., Ohishi, N., and Yagi, K. 1998. Generation ofrecombinant adenovirus vector with
infectious adenoviral genome released from cosmid-based vector by simple procedure
allowing complex manipulation. Biochem. Biophys. Res. Commun. 246(3): 868-872.
Horowitz, M.S., ScharfI: M.D., and Maizel, I.V. 1969. Synthesis and assembly ofadenovirus 2.
I. Polypeptide synthesis, assembly ofcapsomeres and morphogenesis ofthe virion.
Virology. 17: 924-934.
Hua, S., Qui, M., Chan, E., Zhu, L., and Luo, Y. 1997. Minimum Length of Sequence
Homology Required for in Vivo Cloning by Homologous Recombination in Yeast.
Plasmid. 38: 91-96.
Huang, J., and Schneider, R.J. 1991. Adenovirus inhibition ofcellular protein synthesis involves
inactivation of cap binding protein. Cell. 65: 271-280.
139
. - - - - - ....
Ilmer, J.L., Chartier, C., Dreyer, D., Dieterle, A., Sainte-Marie, M., Faure, T., Pavirani, A., and
Mehtali, M. 1996. Novel complementation cell lines derived from human lung carcinoma
A549 cells support the growth ofE1-deleted adenovirus vectors. Gene The. 3: 75-84.
Jones, E. W. and Fink, G., R. (1982). Regulation ofAmino Acid and Nucleotide Synthesis in
Yeast, p. 197-200. In The Molecular Biology of the Yeast Saccharomyces: Metabolism
and Gene Expression, Cold Spring Harbour Laboratory, New York.
Ketner, G., Spencer, F., Tugendreich, S., Connelly, C., and Hieter, P. 1994. Efficient
manipulation ofthe human adenovirus genome as an infectious yeast artificial
chromosome clone. Proc. Natl. Acad. Sci. USA. 91: 6186-6190.
Khilko, S.N., Kirasova, M.A., Kiseleva, E.K., and Tikchonencko, T.I. 1990. Comparison of
adenoviral hexon polypeptide (monomers) and native hexons (trimers) by SDS-
polyacrylamide gel electrophoresis. Acta. Microbiol. Hung. 37: 233-245.
Kim, J.S., Lee, S.H, Cho, Y.S, Park, K., Kim, Y.H., and Lee, J.R. 2001. Development ofa
packaging cell line for propagation ofreplication-deficient adenovirus vector. Exp. Mol.
Med. 33(3): 145-149.
Kitagawa, K., and Abdulle, R. 2002. In Vivo Site-Directed Mutagenesis of Yeast Plasrnids
Using a Three-Fragment Homologous Recombination System. BioTechniques. 33: 288-
294.
Kitajewski, J., Schneider, R.J., Safer, B., Munernitsu, S.M., Samuel, C.E., Thimmappaya, B., and
Shenk, T. 1986. Adenovirus VA RNA antagonizes the antiviral action of the interferon-
induced eIF-2a kinase. Cell. 45: 195-200.
140
Kojima, H., Ohi;hi~N:;-arid Yagi, K~ 1998. Generation ofRecombinant-Adenovirus Vector with
Infectious Adenoviral Genome Released from Cosmid-Based Vector by Simple Procedure
Allowing Complex Manipulation. Biochem. Biophys. Res. Commun. 246: 868-872.
Kuzminov, A. 2001. DNA replication meets genetic exchange: Chromosomal damage and its
repair by homologous recombination. Proc. Natl. Acad. Sci. USA. 98(15): 8461-8468.
Larochelle, N., Oualikene, W., Dunant, P., Massie, B., Karpati, G., Nalbantoglu, J., and
Lochmiiller, H. 2002. The Short MCK1350 PromoterlEnhancer allows for Sufficient
Dystrophin Expression in Skeletal Muscles ofmdx Mice. Biochem. Biophys. Res.
Commun. 292(3): 626-631.
Lechner, R.L., and Kelly, T.J. Jr. 1977. The structure of replicating adenovirus 2 DNA
molecules. Cell. 12: 1007-1020.
Liebowitz, J~, and Horwitz, M.S. 1975. Synthesis and assembly ofadenovirus polypeptide. III.
Reversible inhibition ofhexon assembly in adenovirus type 5 temperature-sensitive
mutants. Virology. 66: 10-24.
Lichy, J.H., Horwitz, M.S. and Hurwitz, J. 1981. Formation ofa covalent complex between the
80,00 dalton adenovirus terminal protein and 5' dCMP in vitro. Proc. Natl. Acad. Sci.
USA. 79: 2678-2682.
Lochmiiller, H., Jani, A., Huard, J., Prescott, S., Simoneau, M., Massie, B., Karpati, G., and
Acsadi, G. 1994. Emergence ofearly region I-containing replication-competent
adenovirus in stocks ofreplication-defective adenovirus recombinants (aEl+aE3) during
multiple passages in 293 cells. Hum. Gene The. 5: 1485-1491.
141
Londberg-Holm, K.,~·and-Philipson, L. 1969. Early events ofthe-virus-cell mteractiorls in an
adenovirus system. J Virol. 4(1): 323-338.
Lorenz, M.C., Muir, R.S., Lim, E., McElver, J., Weber, S.C., and Heitman, J. 1995. Gene
disruption with PCR products in Saccharomyces cerevisiae. Gene. 158: 113-117.
Luftig, R.B., and Weihing, R.R. 1975. Adenovirus binds to rat brain microtubules in vitro. J
Virol. 16(2): 696-706.
Manivasakam, P., Weber, S.C., McElver, J., and Schiestl, R.H. 1995. Micro-Homology
mediated PCR targeting in Saccharomyces cerevisiae. Nucleic Acids Res. 23(14): 2799-
2800.
Mezard, C., and Nicolas, A. 1994. Homologous, Homeologous, and Illegitimate Repair of
Double-Strand Breaks during Transformation ofa Wild-Type Strain and a rad52 Mutant
Strain ofSaccharomyces cerevisiae. Mol. Cell. Bio!. 14(2): 1278-1292.
Mezard, C., Pompon, D., and Nicolas, A. 1994. Recombination between Similar but Not
Identical DNA Sequences during Yeast Transformation Occurs within Short Stretches of
Identity. Cell. 70: 659-670.
McGregory, J., Bautista, D., and Graham, F.L. 1988. A simple technique for the rescue of early
region I mutations into infections human adenovirus type 5. Virology. 163: 614-617.
Miletti, K.E., and Leibowitz, M.J. 2000. Construction ofa large plasmid lacking linearizing
single restriction sites by simultaneous in vivo recombination and plasmid shuftling in
yeast. Yeast. 16: 1527-1534.
142
Miyake, S., Makimura;M-., Kanegae, Y., Harada, S., Sato, Y., Takamori, K.~ -Tokuda,->C., and
Saito, I. 1996. Efficient generation ofrecombinant adenoviruses using adenovirus DNA-
terminal protein complex and a cosmic bearing the full-length virus genome.
Mizuguchi, H., and Kay, M.A. 1998. Efficient Construction ofa Recombinant Adenovirus Vector
by an Improved In Vitro Ligation Method. Human Gene Therapy. 9: 17: 2577-2588.
Moise, A.R., Grant, J.R., Vitalis, T.Z., Jefferies, W.A. 2002. Adenovirus E3-6.7K maintains
calcium homeostasis and prevents apoptosis and arachidonic acid release. J Virol. 76(4):
1578-1587.
New England Biolabs © Inc. Catalog and Technical Reference, 2002-2003.
Ng, P., Parks, R.J., Cummings, C.M., Evelegh, C.M., Sankar, D., and Graham, F.L. 1999. A
high-efficiency CrelloxP-based system for construction ofadenoviral vectors. Hum. Gen.
The. 10: 2667-2672.
Ng, P., Parks, R.J., Cummings, C.M., Evelegh, C.M., and Graham, F.L. 2000. An enhanced
system for construction ofadenoviral vectors by the two-plasmid rescue method. Hum.
Gen. The. 11: 693-699.
Nicklin, S.A., and Baker, A.H. 2002. Tropism-modified adenoviral and adeno-associated viral
vectors for gene therapy. Curro .Gene The. 2(3): 273-293.
Oldenburg, K.R., Vo, K.T., Michaelis, S., and Paddon, C. 1997. Recombination-mediated PCR-
directed plasmid construction in vivo in yeast. Nucleic Acids Res. 25(2): 451-452.
Omelles, D., and Shenk, T. 1991. Localization ofthe adenovirus early region IB 55-kilodalton
protein during lytic infection: association with nuclear viral inclusions requires the early
region 4 34-kilodalton protein. J Virol. 65: 424-439.
143
Parker, R.C., Watson,-R.-M., and Vinograd, J. 1977. Mappmg·of·closed·circular DNAs by
cleavage with restriction endonucleases and calibration by agarose gel electrophoresis.
Proc. Nat!' Acad. Sci. USA. 74(3): 851-855.
Philipson, L. 1984. Adenovirus assembly. In The adenoviruses. Plenum Press, New York.
Qiao, J., Doubrovin,. M., Sauter, B.V., Huang, Y., Guo, Z.S., Balatoni, J.,Akhurst, T., Blasberg,
R.G., Tjuvajev, J.G., Chen, S.H., and Woo, S.L. 2002. Tumor-specific transcriptional
targeting of suicide gene therapy. Gene The. 9(3): 168-175.
Raychaudhuri, P., Bagchi, S., Neil, S.D., and Nevins, J.R. 1990. Activation of the E2F
transcription factor in adenovirus-infected cells involves EIA-dependent stimulation of
DNA-binding activity and induction ofcooperative binding mediated by and £4 gene
product. J. Viro!. 64: 2702-2710.
Raymond, C.K., Pownder, T.A., and Sexson, S.L. 1999. General Method for Plasmid
Construction Using Homologous Recombination. Biotechniques. 26(1): 134-141.
Reich, N., Pine, R., Levy, D., and Darnell, J.E. 1988. Transcription ofthe interferon-stimulated
genes is induced by adenovirus particles, but is suppressed by EIA gene products. J. Virol.
62: 114-119.
Rekosh, D.M.K., Russel, W.C., Bellet, A.J.D., and Robinson, A.J. 1977. Identification ofa
protein linked to the ends of adenovirus DNA. Cell. 11: 283-295.
Ribault, S., Neuville, P., Mechine-Neuville, A., Auge, F., Parlakian, A., Gabbiani, G., Paulin, D.,
and Calenda, V. 2001. Chimeric smooth muscle-specific enhancer/promoters: valuable
tools for adenovirus-mediated cardiovascular gene therapy. Circ. Res. 88(5): 468-475.
144
~ - - - _....
Rosa-Calatrava, M., Grave, L., Puvion-Dutilleul, F., Catton, B., and Kedinger, C. 2001.
Functional analysis ofadenovirus protein IX identifies domains involved in capsid stability,
transcriptional activation, and nuclear reorganization. J Virol. 75(15): 7131-7141.
Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989. Molecular cloning: A Laboratory Manual,
Second Edition. Cold Spring Harbour Laboratory Press, New York.
Santamaria, D., Viguera, E., Martinez-Robles, M.L., Hyrien, 0., Hernandez, P., Krimmer, D.B.,
and Schvartzman, J.B. 2000. Bi-directional replication and random termination. Nucleic
Acids Res. 28(10): 2099-2107.
Schaak, J., Ho, W.Y.-Y., Freimuth, P., and Shenk, T. 1990. Adenovirus terminal protein
mediates both nuclear matrix association and efficient transcription of adenovirus DNA.
Genes Dev. 147: 1197-1208.
Schmid, S.I., and Hearing, P. 1997.. Bipartite Structure and Functional Interdependence of
Adenovirus Type 5 Packaging Elements. J Virol. 71(5): 3375-3384.
Seth, P., Fitzgerald, P.J., Willingham, M.C., and Pastan, I. 1984. Role ofa low-pH environment
in adenovirus enhancement of the toxicity ofa Pseudomonas exotoxin-epidermal growth
factor conjugate. J Virol. 51(2): 650-655.
Shenk, T., and Flint, S.J. 1991. Transcriptional and transforming activities ofthe adenovirus
E1A proteins. Adv. Cancer Res. 57: 47-85.
Shenk, T. Adenoviridae: The Viruses and Their Replication. In Fundamental Virology, Third
Edition, Lippencott-Raven Publishers, Philadelphia.
Souza, D.W., and Armentano, D. 1999. Novel Cloning Method for Recombinant Adenovirus
Construction in Escherichia coli. Biotechniques. 26(3): 502-510.
145
Steenbergh,P.H.~Maa~J~,-'van Ormondt,H. and Sussenbach,J:S". 1977. The nucleotide sequence at
the termini ofadenovirus type 5 DNA. Nucleic Acids Res. 4(12):4371-4389.
Stewart, P.L., Burnett, R.M., CryklatI: M., Fuller, M.D. 1991. Image reconstruction reveals the
complex molecular organization of adenovirus. Cell. 67(1): 145-154.
Sung, P., Miguel Trujillo, K., and Van Komen, S. 1999. Recombination factors of
Saccharomyces cerevisiae. Mut. Res. 451: 257-275.
Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P.N., Curiel, D.T., and Alemany, R. 2001. A
Conditionally Replicative Adenovirus with Enhanced Infectivity Shows improved
Oncolytic Potency. Clin. Can. Res. 7: 120-126.
Svensson, U. 1985. Role ofvesicles during adenovirus 2 internalization into HeLa cells. J.
Virol. 55(1): 442-449.
Szostak, J.W., Orr-Weaver, T.L., Rothstein, R.J., and Stahl, R.W. 1983. The Double-Strand-
Break Repair Model for Recombination. Cell. 33: 25-35.
Tauber, B., and Dobner, T. 2001. Adenovirus early E4 genes in viral oncogenesis. Oncogene.
20(54): 7847-7854.
Tschumper, G., and Carbon, J. (1980). Sequence ofa yeast DNA fragment containing a
chromosomal replicator and the TRP1 gene. Gene. 10 (2): 157-166
van Ginkel, F.W., McGhee, J.R., Liu, C., Simecka, J.W., Yamamoto, M., Frizzell, R.A.,
Sorscher, E.J., Kiyono, H., and Pascual, D.W. 1997. Adenoviral Gene Delivery Elicits
Distinct Pulmonary-Associated T Helper Cell Responses to the Vector and to Its
Transgene. J. Immunol. 159: 685-693.
146
Van Oostru~ J., and -BUrnett, R.M. 1985. Molecular comjJosit-ion of the adenovirus tyPe 2
virion. J Virol. 56(1): 439-448.
Varga, M.J., Weibull, E., and Everitt, E. 1991. Infectious entry pathway of adenovirus type 2.
J Virol. 16: 6061-6070.
Weeratna, R.D., Wu, T., Efler, S.M., Zhang, L., and Davis, H.L. 2001. Designing gene therapy
vectors: avoiding immune response by using tissue-specific promoters. Gene The. 8:
1872-1878.
White, E., and Cipriani, R. 1989. Specific disruptions of intermediate filaments and nuclear
lamina by the 19-kD product of the adenovirus EIB oncogene. Proc. Natl. Acad. Sci.
USA. 86: 9886-9890.
White, E., Cipriani, R., Sabbatini, P., and Denton, A. 1991. Adenovirus EIB 19,000 Dalton
protein overcomes the cytotoxicity of the EIA proteins. J Virol. 65. 2968-2978.
Wickham, T.J., Mathias, P., Cheresh, D.A., and Nemerow, G.R. 1993. Integrins alpha v beta 3
and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 73:
309-319.
Wolfe, A., Kim, H.H., Tobet. S., Stafford, D.E., and Radovick, S. 2002. Identification of a
Discrete Promoter Region ofthe Human GnRH Gene That Is Sufficient for Directing
Neuron-Specific Expression: A Role for POD Homeodomain Transcription Factors. Mol.
Endocrinol. 16(3): 435-449.
Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gonczol, E., and Wilson, J.M. 1994. Cellular
immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl.
Acad. Sci. USA. 91: 4407-4411.
147
Youil, R., Toner~T.J.,--Su;Q., and Kaslow, D.C. 2001. Rapid-method for the isolatiolioffull
length adenoviral genomes by bacterial intermolecular homologous recombination. J.
Virol. Meth. 92: 91-97.
Zambetti, G.P., and Levine, A.I. 1993. A comparison of the biological activities ofwild-type and
mutant p53. FASEB J. 7: 855-865.
